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ABSTRACT 
Neisseria gonorrhoeae (Ng) which causes gonorrhea has become multidrug-
resistant, necessitating the development of novel therapeutics and vaccines. 
mAb 2C7 which targets an epitope within an important virulence factor, the 
lipooligosaccharide (LOS), is a candidate therapeutic mAb. Ninety-four percent of 
clinical isolates express the 2C7-epitope which is also a vaccine target. 
Ng expresses multiple LOS(s) due to phase-variation (pv) of LOS 
glycosyltransferase (lgt) genes. mAb 2C7 reactivity requires a lactose extension 
from the LOS core Heptose (Hep) II (i.e. lgtG ‘ON’ [G+]). Pv results in HepI with: 
two (2-), three (3-), four (4-), or five (5-) hexoses (Hex). How HepI glycans impact 
Ng infectivity and mAb 2C7 function are unknown and form the bases of this 
dissertation. 
Using isogenic mutants, I demonstrate that HepI LOS glycans modulate mAb 
2C7 binding. mAb 2C7 causes complement (C’)-dependent bacteriolysis of three 
(2-Hex/G+, 4-Hex/G+, and 5-Hex/G+) of the HepI mutants in vitro. The 3-Hex/G+ 
mutant (resistant to C’-dependent bacteriolysis) is killed by neutrophils in the 
presence of mAb and C’. In mice, 2- and 3-Hex/G+ infections are significantly 
shorter than 4- and 5-Hex/G+ infections. A chimeric mAb 2C7 that hyperactivates 
C’, attenuates only 4- and 5-Hex/G+ infections. 
 
vii 
This study enhances understanding of the role of HepI LOS pv in gonococcal 
infections and shows that longer HepI glycans are necessary for prolonged 
infections in vivo. This is the first study that predicts in vitro efficacy of mAb 2C7 
against all four targetable HepI glycans thereby strengthening the rationale for 
development of 2C7-epitope based vaccines and therapeutics. 
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CHAPTER I 
Introduction 
  
 
2 
Etiology and epidemiology 
Gonorrhea is the second most common bacterial sexually transmitted infection, 
and is caused by the pathogen Neisseria gonorrhoeae (Ng or gonococcus). 
While earliest references to the disease date back to the Old Testament, the 
second century physician Galen introduced the term gonorrhea to describe 
urethral exudates that he mistook for seminal discharge (gonos [‘seed’] and rhoia 
[‘flow’]). Colloquially, gonorrhea is also called ‘the clap’, a phrase thought to have 
originated in 1378 from Les Clapiers, a district in Paris that was inhabited by sex 
workers (1-3). 
Ng are Gram-negative (Fig. 1), facultatively anaerobic, non-motile (in the 
conventional sense; twitching motility mediated by pili is observed), non-
sporulating cocci that grow in pairs (diplococci) (Fig. 1). Like other members of 
genus Neisseria, they are capnophilic (require 5% CO2), and grow at 
temperatures between 35 – 37 °C. Ng are oxidase (tetra/di-methyl-p-
paraphenylenediamine) positive, but differ from other members of the Neisseria 
sps. in their ability to reduce nitrates to nitrites, and in their ability to ferment only 
glucose. 
An estimated 78.3 million new cases of gonorrhea occur worldwide each year 
(3). In 2012, the highest number of cases were reported from the WHO Western 
Pacific Region, followed by the African Region. The lowest incidence was 
observed in the Eastern Mediterranean and European Regions, while the South-
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East Asia Region and the Region of the Americas reported intermediate 
incidence (3). Within the US, 395,216 cases were reported in the year 2015; a 
12.8% increase compared to 2014, and a 19.9% rise over 2011 rates. Rates of 
gonorrhea increased by 18.3% and 6.8% in men and women, respectively. The 
highest rates of disease were recorded in the 20-24 yrs. age group for both 
sexes. Overall, the rate of infection in women was 107.2 per 100,000 people, 
whereas in men it was 140.9. Across all age groups, the highest rates of infection 
were observed amongst men who had sex with men, whereas women who had 
sex women accounted for the lowest rates. The highest number of cases 
occurred in the African American population, followed by American 
Indians/Alaska Natives and Native Hawaiians/Other Pacific Islanders. Less than 
hundred incidents per 100,000 people were recoded amongst Hispanics, Asians 
and Whites. Geographically, the Southern states reported the highest number of 
cases, followed by the West and the Midwest, whereas the Northeast had the 
least number of cases (4).  
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Figure 1. Gram-stained Neisseria gonorrhoeae (Ng). Ng are Gram-negative 
cocci that occur in pairs (diplococci). An isolated colony from an overnight culture 
of MS11 WT on chocolate agar was suspended in normal saline (0.9% NaCl) and 
spread on a clean glass slide. Subsequently, the smear was air dried and heat 
fixed. The slide was stained with crystal violet (1 min), fixed with Gram’s iodine (1 
min), decolorized with acetone-ethanol (1:1 ratio, 30 sec) and finally 
counterstained with safranin (45 sec). The smear was visualized under a 100x 
oil-immersion (1000x magnification).  
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Clinical symptoms 
Uncomplicated gonorrhea is an acute, often self-resolving and localized infection, 
characterized by inflammation of the genitourinary mucosae including the 
urethra, vagina, endocervix, rectum, and pharynx (5). In men, gonorrhea 
primarily manifests as acute urethritis characterized by a purulent discharge. It is 
often accompanied by dysuria but without frequency or urgency. Incubation 
periods range from 1-10 days, though symptoms typically appear within 2-5 days. 
Although most infections in men are clinically overt, a small proportion remain 
asymptomatic. Complications of gonorrhea in men include epididymitis, penile 
edema, lymphangitis, periurethral abscesses, prostatitis, seminal vesiculitis and 
infections of the Tyson’s and Cowper’s glands (6). 
In women, the primary site of gonococcal infection is the endocervix, although N. 
gonorrhoeae may be isolated from the urethra, rectum, Skene’s and Bartholin’s 
glands. Incubation periods in women are not well established, although 
symptoms usually occur within 10 days of infection. Symptoms of gonococcal 
infections in women include cervicitis that manifests as increased vaginal 
discharge, urethritis, dysuria (usually without frequency or urgency), and 
intermenstrual bleeding. A frequent complication of gonococcal infection in 
women is pelvic inflammatory disease (6). Other complications of gonococcal 
infections include perihepatitis (the result of spillage from the fallopian tubes and 
spread through the peritoneal cavity), anorectal, and pharyngeal gonorrhea. 
 
6 
According to some reports as many as 90% of women, are asymptomatic and 
have subclinical infection. Coinfections with Chlamydia trachomatis and 
Trichomonas vaginalis are also common (6). 
In rare cases, gonococcal bacteremia may result in disseminated gonococcal 
infections characterized by septic arthritis, polyarthritis and dermatitis. Newborns 
may contract gonococcal infections during passage through the birth canal. 
Gonococcal infections in infants typically manifest as conjunctivitis, known as 
ophthalmia neonatorum.  
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Laboratory diagnosis of gonococcal infections 
Samples are usually collected using rayon, Dacron or calcium alginate tipped 
swabs on a plastic or wire shaft (cotton swabs are unsuitable because fatty acids 
that are present in cotton may inhibit the growth of gonococci). Swabs are 
inserted between 1 – 3 cm into the endocervical canal or the male urethra to 
collect specimens. If transport is required, Amies charcoal media or Jembec 
chambers with modified New York City or Thayer-Martin media may been used. 
Nowadays, several commercial transport media are available which support 
better survival of Ng (7, 8). For males, Gram stained smears of the specimen are 
diagnostic if neutrophils or polymorphonuclear leukocytes (PMNs) with 
intracellular Gram-negative Ng are observed (sensitivity > 99%, specificity 
>95%). For females, the endocervical canal is colonized with non-pathogenic 
Neisseria sps. and Gram staining is not specific. Additionally, pharyngeal and 
rectal specimens are also unsuitable for diagnosis by Gram’s stain because of 
the presence of N. meningitidis and other commensal Neisseriae. Sterile 
specimens are cultured on chocolate agar, while non-sterile specimens are 
cultured on Thayer-Martin, or Martin-Lewis medium (9) at 37 °C with 5% CO2 
(10). Ng have to be biochemically distinguished from other Gram-negative 
oxidase-positive cocci. Most other species of Neisseria ferment both glucose and 
maltose (N. meningitidis, N. lactamica, N. polysaccharea N. subflava, N. sicca, N. 
mucosa), or neither (N. cinerea, N. flavescens, N. elongata). Moraxella 
catarrhalis are also oxidase-positive, Gram-negative cocci, but do not ferment 
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any carbohydrates used for standard biochemical diagnosis. On the basis of 
standard biochemical reactions Ng may be confused with Kingella denitrificans 
(Gram-negative coccobacilli) since they both ferment only glucose and no other 
carbohydrates; but they are readily distinguished from the latter, which cannot 
reduce nitrates (11). Nowadays, most clinical centers diagnose gonorrhea using 
one of the FDA approved nucleic acid amplification tests (NAATs). These tests 
have high sensitivity and specificity and their test performance characteristics on 
urine are similar to samples obtained from the genital tract (12-15). Further, the 
samples are stable at room temperature for long periods, which facilitates 
transportation. The ease of sample collection and processing makes NAATs the 
test of choice for screening of large populations. NAATs, however, do not permit 
detection of drug resistant strains, which requires culture. Antibiotic susceptibility 
assays are usually performed using the modified Kirby-Bauer disk diffusion 
method or E-test (not approved for cefixime) using Ng ATCC 43069 as a control 
strain (16).  
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Pathogenesis of gonorrhea 
The pathogenesis of Ng remains poorly understood. It is thought that in women, 
Ng get opsonized with the complement (C’) protein C3 fragments (C3b and iC3b) 
within the cervix (17). The C3b/iC3b then mediates entry into the cervical 
epithelia via complement receptor 3 (CR3; CD11b/CD18) that is present on 
primary cervical epithelial cells (18). Entry is facilitated by formation of ezrin and 
vinculin-rich focal complexes followed by membrane ruffling (19). Following their 
entry into cervical epithelial cells, gonococcal phospholipase D (NgPLD) 
upregulates CR3 expression, which allows further infection (20). The exact role 
of NgPLD remains yet to be determined. The expression of CR3 gradually 
decreases with ascension in the female genital tract. Concomitantly, the 
expression of lutropin receptor (LHr) increases (21)which recognize the 
gonococcal moonlighting protein L12 (22, 23). It is thought that Ng infects the 
epithelium of the female upper genital tract via LHr receptors (24). In the upper 
tract, Ng interacts with non-ciliated tubal epithelium although only ciliated 
epithelial cells are shed (24). Gonococcal lipooligosaccharide (LOS) (25-29) and 
peptidoglycan (PG) (30) also have a cytotoxic effect on tubal epithelium, which 
leads to a surge in pro-inflammatory cytokines such as TNF-α (29). Some, but 
not all, studies report the presence of TNF-α, IL-1β, IL-6, and IL-8 in endocervical 
secretions (31). 
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In males, the gonococcal LOS interacts with the asialoglycoprotein receptor 
(ASGP-R) on urethral epithelial cells (32). Data from clinical specimens as well 
as primary cell cultures reveal that endocytosis of Ng occurs via actin- (33) and 
clathrin- (34) dependent processes subsequent to pedestal formation secondary 
to Ng–ASGP-R interactions (34). Ng are then transcytosed across the cell 
leading to the spread of infection. LOS also triggers the secretion of TNF-α, IL-
1β, IL-6, and IL-8 from the urethral epithelium. Chemokine and cytokine release 
leads to the influx of a large number of a large number of PMNs which is the 
pathognomonic feature of gonorrhea (31). 
In the absence of opsonins, gonococci not only survive and multiply within PMNs, 
but also induce inflammatory responses which exacerbate the pathology (22, 35). 
In order to survive the oxidative burst inside PMNs, gonococci elaborate several 
virulence factors such as catalase, cytochrome oxidase, superoxide dismutase, 
manganese transport systems, DNA and protein repair systems including MutY, 
RecA, Uvr and MsrAB, and the metalloproteinase NGO1686. Gonococci can also 
resist non-oxidative killing using factors such as multiple transferable resistance 
system (MtrCDE) and fatty acid resistance system (FarAB) efflux pumps, MisRS, 
and peptidoglycan O- acyltransferase (PacA) (22). The gonococcal porin (Por) 
also inhibits phagocytosis and subsequent killing via diverse mechanisms (31). 
Inside neutrophils, the gonococcal LOS becomes sialylated and must be 
desialylated in order to enable invasion of male urethral epithelial cells but not 
the female cervical epithelia. Neuraminidases present on spermatozoa, cervical 
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epithelial cells, neutrophils, and macrophages de-sialylate gonococci, which 
facilitates disease transmission to males. It is thought that desialylated gonococci 
attach to the ASGP-R on surface of spermatozoa during transmission from males 
to females (31, 36).  
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Antibiotic resistance in Neisseria gonorrhoeae 
Neisseria gonorrhoeae has become extremely drug resistant. A case-report from 
2014 describes a multidrug resistant Ng isolated in the UK, but acquired in 
Japan. In this instance, Ng had acquired resistance to combination therapy 
comprising ceftriaxone (a third-generation cephalosporin) and azithromycin (a 
macrolide) (37). A combination of ceftriaxone and azithromycin is currently the 
CDC recommended treatment regimen for Ng (38). 
Before the 1930s Ng infections were treated with potassium permanganate 
(KMnO4), silver compounds, herbs and hypothermia (39). With the advent of 
antibiotics, Ng was amenable to treatment with sulfonamides (40) and penicillin 
(41). However, by the mid-1940s Ng had acquired resistance to sulfonamides 
(42), and by the late-1940s resistance to penicillin (introduced in mid-1940s) had 
begun to emerge (43-47). By the 1960s treatments with spectinomycin and 
tetracyclines had become commonplace. However, the efficacy of these 
antibiotics too, was short-lived; spectinomycin resistance was reported in the late 
1960s (48) and tetracycline resistance was observed in the early to mid-1980s 
(49). Between 1990 and 2000, strains of Ng were reported that were resistant to 
fluoroquinolones (50-52), macrolides (53-59), and some third generation 
cephalosporins (cefixime) (60-62). High-level resistance to ceftriaxone was first 
reported in 2010 (63). Subsequently, treatment failures with ceftriaxone have 
been reported from Japan, Europe, UK, Canada, Australia, and South Africa. It is 
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predicted by some experts that by 2020 circulating strains of Ng will be 
untreatable using conventional antibiotics (37, 64, 65).  
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Development of vaccines against gonorrhea 
Currently, there are no safe and effective vaccines against gonorrhea. Multiple 
factors have stymied the development of vaccines directed against Ng. The 
primary reason has been the lack of a conserved broadly protective antigen (Ag) 
for targeting. Most targetable Ng Ag(s) are variably expressed across strains, 
and those that are expressed, undergo widespread Ag variation. Moreover, the 
correlates of protection against gonorrhea remain unknown. Finally, the lack of a 
reliable small animal model has also hindered vaccine development. 
Only two vaccine candidates, purified pilin (Pil) and killed whole cells, have 
undergone human clinical trials, and unfortunately, both failed to confer 
protection against infection (66). The purified Pil-based vaccine comprising PilE 
(fibril) and low amounts of PilC (minor pilus associated protein) elicited a good 
antigenic response with the production of antibodies (Ab[s]) that were bactericidal 
in vitro. However, Pil is a highly variable Ag and the vaccine failed to confer 
protection in humans challenged with Ng strains expressing heterologous Pil. 
The crude killed whole cell vaccine trial conducted in a Inuit population in 
Northern Canada was well tolerated, but also not protective (67). 
Several gonococcal Ag(s) have been reported to be immunogenic, but only three 
have demonstrated efficacy in the mouse vaginal infection/colonization model 
(68). In female mice immunized (intra-nasally) with outer membrane (OM) 
preparations, Ng specific immunoglobulin (Ig) G(s) and IgA(s) reactive with 
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multiple targets were identified from vaginal washings. Serum from immunized 
mice were also shown to be bactericidal. However, the identity of the targets 
were not characterized (69). In another study, replicating viruses were employed 
to immunize mice with refolded recombinant Por B (68). Another candidate 
vaccine is a peptide mimic (‘mimitope’) of a LOS epitope that is expressed 
broadly and is important for virulence (70). This LOS epitope forms the basis of 
this thesis and has been described later.  
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Lipooligosaccharide — a ubiquitous and immunogenic virulence factor 
LOS, or lipopolysaccharide (LPS) is the most abundant component of Gram-
negative OM (Fig. 2). Both the LOS and the LPS have a hydrophobic lipid A and 
a core oligosaccharide (OS) comprising 2-Keto-3-Deoxy-D-manno-octonates 
(KDO), heptoses (Hep), and hexoses (Hex; usually 6 or less) extending from the 
Hep residues (Fig. 3). While LOS contains only the core OSs, LPS is 
characterized by repeating O-linked glycans extending from the core OS (Fig. 3) 
(71). 
LOS is also an important gonococcal virulence factor. It mediates attachment to 
the ASGP-R on spermatozoa and epithelial cells to facilitate transmission and 
local spread of infection, respectively (31). Moreover, amounts of LOS as little as 
0.015 µg/mL impair ciliary activity and lead to necrosis of the tubal epithelium 
(28, 72). Furthermore, LOS lipid A and heptose-1,7-bisphosphate can lead to NF-
κB activation via TLR4-MyD88 (73, 74) or TIFA dependent (75) pathways 
respectively. Activation of NF-κB results in synthesis of pro-inflammatory 
cytokines such as TNF-α, IL-1β, IL-6, and IL-8 (76). This cytokine storm causes 
the influx of the large number of PMNs, a hallmark of gonococcal infections. A 
majority of gonococcal infections however are asymptomatic, especially in 
women. Gonococcal LOS can upregulate Type I interferons (IFN) such as IFN-β 
via the TLR4 – TRIF-dependent pathway (73). IFN-β suppresses gonococcal 
killing and may promote a carrier like state (73). 
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C’ is an important anti-Neisserial defense mechanism (77-79).TNF-α, IL-1, and 
IL-6 upregulate synthesis of acute phase mediators such as C4-binding protein 
(C4BP) (80). Some strains of Ng can bind C4BP via their Por(s) and resist the 
deleterious effects of the classical C’ pathway (81). Acquisition of the ability to 
resist to complement enhances virulence of Ng. Ng can scavenge CMP-Neu5Ac 
from the host to sialylate its LOS, which enables Ng to bind factor H (FH) which 
makes them resistant to the alternate pathway of C’ (82). Sialylation may also 
decrease binding of IgG, thereby inhibiting the classical pathway as well (83). 
The gonococcal LOS is also immunogenic. Several anti-LOS antibodies (Ab[s]) 
have been isolated from normal human serum (NHS). These Ab(s) have been 
described to bind different epitopes including the outer OS(s) as well as the 
buried KDO(s) (84). Furthermore, some of the Ab(s) activated the classical C’ 
pathway and were bactericidal (85). Given its ubiquitous distribution, its critical 
role in pathogenesis and its immunogenicity, LOS represents an attractive target 
for a vaccine or an antibody based therapeutic.  
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Figure 2. The Gram-negative cell membrane. The Gram-negative cell membrane 
comprises two phospholipid bilayers with a layer of peptidoglycan in-between. 
Proteins are embedded in both the outer and the inner membranes. The 
lipooligosaccharide (LOS) or lipopolysaccharide (LPS) is present in the outer 
membrane facing the extra-cellular milieu. The LOS or LPS (boxed) is the most 
abundant molecule in the Gram-negative outer membrane.  
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Figure 3. Schematic representation of the LOS and LPS. The Gram-negative 
LPS molecule has three parts;(i) Lipid A which is hydrophobic and anchors LPS 
to the outer membrane, (ii) the core oligosaccharide (OS) comprising the 2-Keto-
3-Deoxy-D-manno-octonic acid (KDO) residues, two Heptoses (Hep), and up to 
six Hexose (Hex) residues, and (iii) and the repeating O-linked Hex(s). LPS is 
usually expressed by members of the Enterobacteriaceae family such as 
Salmonella sps., Shigella sps., Klebsiella sps., and other Gram-negative 
organisms such as Pseudomonas sps. In organisms such as Neisseria sps. and 
Haemophilus sps. that are not normally exposed to biliary acids, the repeating O-
linked Hex(s) are absent; only the Lipid A and the core OS is present; this 
molecule is called the lipooligosaccharide or LOS.  
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Ng LOS is targeted by monoclonal antibody (mAb) 2C7 
In the 1990s several mAb(s) that reacted with the gonococcal LOS, including 
mAb 2C7, were generated. mAb 2C7 (IgG3λ) was originally obtained from 
splenic B-cells of mice immunized with outer membrane vesicle preparations 
from the Ng strain WG, specifically to characterize LOS. Subsequently, the B-
cells were fused to the murine myeloma cell line Sp2/0-Ag14 to generate stable 
hybridomas (86). In a study conducted in Boston, >94% of clinical isolates 
reacted with this antibody (87). In more recent studies conducted by our group 
using minimally passaged isolates from a STI clinic in Nanjing, China, 100% of 
the isolates reacted with this mAb (Sunita Gulati – personal communication). O-
deacylated LOS was acid hydrolyzed to liberate lipid A, and the remaining OS 
component was analyzed by mass spectrometry. Subsequently, the mAb 2C7 
epitope was determined to consist of a β-linked lactose from HepI (Gal-β1,4-Glc-
β1,4-HepI) and an α-linked lactose from HepII (Gal-β1,4-Glc-α1,3-HepII) (88). 
The LOS epitope recognized by mAb 2C7 appears not only to be widely 
expressed, but is also important for pathogenesis. In a murine infection model of 
vaginal colonization, knocking out the 2C7 epitope attenuates Ng infection (70). 
Furthermore, it has been observed that serial passage of laboratory Ng strains 
that initially poorly colonize mouse vaginal tracts results in progressively exalted 
infection in vivo. Whole genome sequencing established increased expression of 
the mAb 2C7 epitope as a result of lgtG becoming phase-varied ‘ON’, and 
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constitute a probable explanation for enhanced bacterial infectivity in mice (89). 
Therefore, the mAb 2C7 epitope within the Ng LOS forms an excellent target for 
immunotherapeutic and vaccine Ab(s). 
In the murine vaginal colonization model, passive immunization with mAb 2C7 
shortens the duration and burden of bacterial infection. Furthermore, active 
immunization with a peptide mimic of the mAb 2C7 epitope also resulted in 
transient infections and lower bacterial burdens (70, 87). The Ab response to 
vaccination was specific to the mAb 2C7 epitope because no Ab binding was 
detected against Ng lacking this epitope. The anti-LOS Ab repertoire comprised 
IgM, IgA, and IgG (IgG1, IgG2a, IgG2b, and IgG3) (70). Thus, mAb 2C7 forms 
the basis of an anti-gonococcal immunotherapeutic, while a peptide mimic of its 
epitope is being developed as a candidate vaccine.  
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mAb 2C7 activates the classical complement cascade 
The correlate(s) of protection against gonococcal infections remain to be fully 
elucidated. However, C’ mediated defenses are believed to play a critical role 
against gonorrhea for the following reasons. First, C’ deficiencies are associated 
with recurrent Neisserial infections (77, 79, 90). Second, C’-dependent serum 
bactericidal activity mediated by immune Ab is the correlate of protection against 
the closely related pathogen Neisseria meningitidis (91). Thus, although the 
mechanism whereby mAb 2C7 attenuates gonococcal infection in the 
experimental murine model is unknown, work thus far has focused on its ability to 
activate the classical C’ pathway and kill Ng in C’-dependent serum bactericidal 
assays. 
Antibodies activate the classical C’ cascade (Fig. 4) via their Fc regions. Human 
IgG subclasses differ in their ability to activate C’. In general, human IgGs 
activate C’ in the order: IgG3>IgG1>IgG2, while IgG4 does not activate C’. In 
contrast to IgG, where the cooperation between six molecules is required to 
activate C’ (92), a single IgM molecule can activate C’. This is because IgM is 
polymer (pentameric or hexameric in the presence or absence of the J chain, 
respectively) and each target-bound IgM can bind to a C1 complex (93, 94). 
Thus, on a molar basis, IgM is the most potent activator of the classical pathway. 
The classical pathway is usually initiated by binding of antibodies to their target 
antigens. Binding of an antibody to its target exposes a binding site for the 
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trimolecular C1 complex that comprises a hexameric C1q, which binds Fc, and 
two molecules each of C1r and C1s. A single globular head of C1q and Fc 
interact with very low affinity (Kd ≈10-4 M) (95, 96). However, above a certain 
critical epitope density, Fc domains form hexamers, which then engage each of 
the six globular heads C1q molecule and results in a high avidity C1q-Fc 
interaction (97, 98). C1r and C1s are arranged as a tetramer (C1s-C1r-C1r-C1s) 
and form a Ca2+ dependent catalytic subunit (99, 100). Binding of C1q generates 
a conformational signal that results in auto-activation of C1r, which in turn 
activates C1s. Some authors suggest intramolecular activation of C1r by C1s is a 
conformational improbability. Their data suggests C1r activates C1s in a 
neighboring C1 complex (101). Both molecules are activated through cleavage of 
an Arg-Ile bond. 
Activated C1s cleaves the 77-amino acid C4a fragment from the N-terminus of 
the α-chain of C4 to form the metastable C4b molecule. This exposes the internal 
thioester bond of C4b (102) that can react readily with nucleophilic (i.e., electron-
donating groups) groups such as –OH or −NH2 on surfaces to form covalent ester 
or amide bonds, respectively (103). If the nascent carbonyl group in the thioester 
moiety does not interact with a surface, it will react with water and remain in 
solution. There are two isoforms of C4 expressed by most humans, called C4A 
and C4B (104), which dictates the type of bond formed by C4b (note that C4a 
and C4b represent activation products of C4 and are distinct from the C4A and 
C4B isoforms of intact C4). C4B possesses a His residue at position 1106 in the 
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α-chain, which imparts to C4B the ability to form ester linkages, while an Asp 
residue at position 1106 results in ‘C4A-like’ functionality and preferential amide 
bond formation (105). 
In the next step in classical pathway activation, C2 binds to C4b deposited on a 
surface. C2 is also cleaved by activated C1s into the C2a fragment, which 
remains attached noncovalently to C4b and C2b, which is released into solution. 
C4b2a forms the C3 convertase (C3 cleaving enzyme) of the classical pathway. 
In this manner, a single C1 complex can cleave several substrate molecules and 
augment C’ activation. Formation of the classical pathway C3 convertase can be 
inhibited by C4BP. C4BP inhibits the classical pathway by two major 
mechanisms: i) acts a cofactor in the factor I (FI)–mediated cleavage of C4b to 
C4c and C4d, and ii) accelerates dissociation of C2a from the classical pathway 
C3 convertase (C4bC2a), a property called ‘decay-accelerating’ activity (106-
109). 
All C’ pathways converge at the level of C3. C3 is the most abundant C’ 
component (plasma concentrations range from 1.0 to 1.5 mg/ml) and its 
fragments serve a variety of functions. C3 fragments deposited on surfaces are 
opsonins for phagocytes and the anaphylatoxin C3a modulates inflammation, 
lipid metabolism (C3a-desArg, which is generated by cleavage of the C-terminal 
Arg by carboxypeptidase N is also called acylation stimulating protein) and tissue 
regeneration. Similar to C4, the α-chain of C3 also possesses an internal 
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thioester moiety that forms stable, covalent bonds with target surfaces. Cleavage 
of the C3a fragment from C3 results in activation of C3 is accompanied by 
marked structural rearrangements among its various domains. Most notably, the 
thioester domain that is tucked away in the native molecule becomes completely 
exposed and capable of reacting with nucleophiles (110). The thioester forms a 
highly reactive acyl-imidazole intermediate with an extremely short calculated 
half-life of ≈30 µs (111). If this reactive group does not bind to a surface –OH (or 
in some instances, a –NH2 group) within this short period, it will react with a water 
molecule and remain in solution. The high reactivity and short duration of the 
nascent thioester domain restricts C3 deposition to structures proximate to the 
site of C3 activation, while sparing more distant (and possibly normal) tissue from 
unwanted damage. 
Binding of an additional C3b molecule to C3 convertase generates the C5 
convertase (C4bC2aC3b) that can cleave C5 and initiate the assembly of 
membrane attack complex (MAC). C5 bears structural homology with C3 and C4, 
but lacks a thioester domain. The addition of C3b to C3 convertases alters the Km 
for C5 >1000-fold, from far above the physiological concentration of C5 to far 
below it (112-114). Therefore, situations that favor C’ activation and rapid C3b 
generation also facilitate the generation of cytolytic MAC. Cleavage of C5 results 
in release of the ≈11 kDa C5a fragment, a key anaphylatoxin with diverse 
functions. Removal of the C-terminal Arg residue from C5a by carboxypeptidase 
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N results in formation of C5a-desArg, which retains only 1-10% of the 
inflammatory activity of C5a (115).  
Binding of C5b to hydrophobic sites on cell surfaces exposes binding sites for C6 
and C7 to form the C5b-7 complex. Incorporation of C7 confers amphiphilic 
properties to the assembling MAC and permits direct insertion into cell 
membranes. C8 then binds to the β-chain of C5b, followed by the addition of one 
or more C9 molecules. C6, C7, C8 and C9 all belong to the MACPF/CDC (MAC-
perforin/cholesterol dependent cytolysin) superfamily of proteins (116, 117), 
which contain a common set of four core domains; from the N- to C-terminus, a 
thrombospondin-1 (TSP1) domain, a low-density lipoprotein receptor-associated 
(LDLRA) domain, a MACPF domain and an epidermal growth factor (EGF) 
domain. In its fully assembled state, MAC comprises one molecule each of C5b, 
C6, C7 and C8 and up to 18 molecules of C9. The ring-like membrane 
configuration of MAC is dependent on C9 polymerization. C9 in its free 
monomeric native state has a globular conformation (118). Upon polymerization, 
C9 adopts a tubular structure, where the external aspect of the tubule is 
hydrophobic and intercalates into membranes, while the inner aspect of the pore 
is hydrophilic and permits passage of water and ions. While most other pore-
forming proteins rely on interactions solely between their MACPF domains, 
structural studies of poly-C9 revealed unexpected interactions between the TSP1 
domain and the MACPF domain of adjacent monomers (119). The TSP1-MACPF 
interactions permit recruitment of C9 molecules from solution into the nascent 
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membrane-associated MAC complex. Cryo-electron microscopy analysis of the 
entire C5b-9 complex revealed a ‘split-washer’ configuration, as opposed to a 
symmetric closed-ring conformation seen with perforin and other cholesterol-
dependent cytolysins (120). Disruption of the membrane proton motive force 
during pore formation and osmotic damage mediated by the channel may both 
contribute to the cytolytic action of MAC. Formation of MAC is thought to be the 
primary mechanism of action of mAb 2C7.  
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Figure 4. The classical complement (C’) cascade. Ab (IgG/IgM) binds to the 
surface of the target cells/Ag. The globular heads of the hexameric C1q engages 
amino acid residues in the Fc region of the Ab. The affinity of an individual C1q 
head for the Fc region is very low, so multiple globular heads of the same C1q 
molecule must be engaged by multiple Ab(s). This not only enhances the avidity 
of C1q for the Ag – Ab complex, but also brings about a conformational change 
such leading to intermolecular or intramolecular activation of C1s by C1r. C1s 
cleaves C4 into C4a and C4b. C4b gets deposited on the surface of the target 
forming amide or ester linkages on account of its internal thioester bonds 
reacting with – NH2 or – OH groups. C2 which then binds to C4b is also cleaved 
by C1s into C2a and C2b. C2a remains non-covalently attached to C4b. The 
C4b2a complex forms the classical pathway C3 convertase which cleaves C3 
into C3a and C3b. Binding of C3b to C4b2a generated the classical pathway C5 
convertase (C4b2a3b). The C5 convertase cleaves C5 into C5a and C5b. 
Binding of C5b to hydrophobic surfaces exposes binding sites for C6 and C7 
forming the C5b-7 complex. Incorporation of C7 imparts amphiphilic properties to 
the assembling Membrane Attack Complex (MAC). C8 then binds to the β-chain 
of C5b followed by the addition of one or more C9. C8 is the first protein of the C’ 
cascade to insert into the membrane. Multiple C9 molecules come together to 
form a spit washer like pore which leads to the osmotic lysis of cells. The 
liberated C3a, C4a, and C5a function as anaphylatoxins with diverse functions.  
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Gaps in knowledge of mAb 2C7 biology 
Murine protection experiments with the mAb 2C7 antibody were done with wild 
type (WT) FA1090 (70). Unpublished observations based on mAb 3F11-reactivity 
(121) show that the WT FA1090 used in the animal experiments predominantly 
express the 4-Hex/G+ LOS, or the lacto-N-neotetraose (LNnT) structure. Hexose 
extensions from gonococcal heptoses, however, are highly variable and Ng can 
express up to eight different LOS structures because of random switching ‘ON’ 
and ‘OFF’ of four phase-variable (pv) lipooligosaccharide glycosyl transferase 
(lgt) genes: lgtA, lgtC, lgtD, and lgtG (122-124) (Fig. 5). Of these, lgtG is ‘virtually’ 
‘ON’ in vivo, resulting in the expression of the mAb 2C7 epitope (87, 89). The 
basis of pv of the gonococcal LOS is the presence of homo-polymeric poly-G/C 
tracts within the coding regions of the lgt genes, which leads to slipped-strand 
mispairing (SSM) primarily during DNA replication (123, 124). In SSM, loops are 
formed during DNA replication (Fig. 6). If the loop is formed in the template 
strand, it leads to deletion of nucleotides in one of the progeny. If the looping 
occurs in the nascent strand, it results in addition of nucleotides. Either of these 
events (addition or deletion of C/Gs) can throw an ‘in frame’ coding sequence out 
of frame, or conversely can restore an out of frame coding sequence back in 
frame. SSM of lgtA, lgtC, and lgtD in the presence of an in-frame lgtG 
(henceforth referred to as G+) results in the expression of at least four distinct 
LOS structures (2-Hex/G+, 3-Hex/G+, 4-Hex/G+, and 5-Hex/G+), each of which 
possesses the ‘minimal’ mAb 2C7 epitope (Fig. 7). Of these, WT FA1090 
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predominantly expresses a 4-Hex/G+ LOS structure. While all four LOS 
structures are represented in clinical isolates, the relative importance of each of 
these structures in pathogenesis is not fully understood. Further, how HepI 
glycan extensions (i.e., the structures expressed because of phase variation of 
lgtA, lgtC and lgtD) affect mAb 2C7 binding and function remains to be 
determined. 
The WT FA1090 that has been used in mAb 2C7 protection studies (70) is a 
relatively avirulent strain (125). In human experimental urethral infections the 
infectious dose for this strain has been established to be ~100-fold orders higher 
than strains such as MS11 (126). MS11, along with eighty percent of circulating 
Ng strains possesses a 57-kb Gonococcal Genetic Island (GGI) (127). Although 
the function of the GGI is unknown, it is associated with anti-microbial resistance 
(128). Moreover, it is thought to encode a lytic transglycosylase (ltgA) which 
cleaves PG to form a peptidoglycan-derived cytotoxin (PGCT). Sinha and 
Rosenthal have established that the most abundant Ng PG released into the 
surrounding milieu is similar to the Bordetella pertussis PGCT which is pro-
inflammatory and causes IL-1 and Il-6 release (129). Such pro-inflammatory 
cytokines can enhance Ng virulence (as described earlier). WT FA1090 used in 
mAb 2C7 protection studies (70) also lacks the GGI which may be an important 
virulence determinant. 
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Further, WT FA1090 lacks lactoferrin-binding proteins (Lbp) A and B. Thus, it can 
scavenge iron only from transferrin (Tf). Iron is an important growth factor for Ng, 
and is available from lactoferrin (Lf) as well as transferrin. In experimental human 
studies where volunteers were challenged with a mixture of equal numbers of 
WT FA1090 (Tf+Lf-) and a Tf+Lf+ FA1090 mutant, by day 4 or 5, 100% of 
recovered isolates were the Tf+Lf+ mutant (130). About half of the circulating Ng 
strains have a Tf+Lf- phenotype, while the other half have a Tf+Lf+ phenotype. It 
is therefore interesting to note that the strain (MS11) shown to have a lower ID50 
than FA1090 in vivo has a Tf+Lf+ phenotype (126).  
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Figure 5. Schematic 
Representation of the 
Phase-variable (pv) 
Ng LOS. Ng 
expresses a LOS, 
meaning it has a 
hexacylated Lipid A 
O-linked to the core 
OS comprising two 
KDO(s), two Hep(s), 
and Hex extensions 
emanating from HepI 
and HepII, but lacks 
the O-linked 
repeating sugars. Ng 
can express up to 
eight distinct LOS structures. Variation in the Ng LOS is due to pv of four 
lipooligosaccharide glycosyltransferase (lgt) genes (indicated within black boxes); 
lgtA, lgtC, lgtD, and lgtG. These genes encode enzymes that catalyze addition of 
Hex(s) to the Hep(s). Two other lgt genes, lgtF and lgtE are constitutively 
expressed and responsible for the extension of a lactose adduct from HepI. 
Thus, this is the LOS structure that Ng would express when all four pv genes are 
‘OFF’. Expression of lgtG is almost always ‘ON’ (>94% clinical samples are mAb 
2C7-positive), and this results in the addition of a lactose moiety to HepII. The 
HepI and HepII lactoses together make up the mAb 2C7 epitope (shaded in 
gray). Depending on the combinations in which lgtA, lgtC, or lgtD are ‘ON’ or 
‘OFF’, two, three, four, or five Hex(s) may be extended from HepI. The table 
denotes the four possible Ng LOS structures (in >94% of samples) and their 
genotypes.  
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Figure 6. Phase-variation (pv) of the lgt genes. As discussed earlier, variation in 
the Ng LOS structure is due to pv in four of the lgt genes; lgtA, lgtC, lgtD, and 
lgtG. Presence of homopolymeric poly-G or poly-C tracts within the coding 
sequence of these genes allow them to be turned ‘ON’ or ‘OFF’ during DNA 
replication by a process known as ‘slipped-strand mispairing’ (SSM). During DNA 
replication, the presence of homopolymeric (poly-G/C) tracts may sometimes 
lead to formation of loops. If the loops form in the nascent (replicating) strand, it 
leads to addition of nucleotides in one of the two progenies. If, the event occurs 
in the template strand nucleotides are deleted. Assuming the looping event 
occurs in one of the two parental DNA strands, one of the progenies maintain the 
parental DNA sequence. An addition or deletion can throw an ‘in frame’ coding 
sequence ‘out of frame’ or vice-versa thereby regulating the expression of the 
corresponding enzymes. This culminates in the expression of different LOS 
structures.  
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Figure 7. The four LOS structures expressed by >94% clinical isolates of Ng. 
More than 94% of the clinical isolates of Ng have the lgtG turned ‘ON’ (G+) 
thereby expressing the HepII lactose which makes them mAb 2C7 reactive. 
Depending on the combination in which the other three pv genes are turned on or 
off, Ng can express four different LOS structures: 2-Hex/G+, 3-Hex/G+, 4-
Hex/G+, and 5-Hex/G+ (clockwise from top left). Most Ng express more than one 
LOS structures, although the proportion in which they do so in vivo is variable.  
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Scope and specific aims of this dissertation 
Will a murine mAb 2C7 epitope-based vaccine be effective against all four 
distinct Ng LOS structures that can theoretically be recognized by the Ab? Is 
murine mAb 2C7 effective in vitro against more virulent Ng strains with lower 
infectious doses (such as MS11)? Do HepI glycan structures impact infectivity in 
the mouse vaginal colonization model? These were the major unanswered 
questions surrounding the efficacy of a mAb 2C7-epitope based vaccine that this 
dissertation sought to shed light on. 
In light of data obtained over the course of the above studies, I also proceeded to 
ask whether murine mAb 2C7 could be developed as a therapeutic antibody 
against multidrug-resistant N. gonorrhoeae. And, would such a therapeutic be 
effective in vitro and in vivo against all 2C7-positive LOS glycoforms? As a first 
step to answer these questions, a chimeric mAb 2C7 (2C7-Ximab) was created 
in collaboration with Genmab B.V. The Fc region of 2C7-Ximab was further 
modified to enhance its C’ activating properties. Thus, I also asked whether this 
modification conferred any advantage over a chimeric with a native (WT) Fc?  
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The specific aims of this dissertation were: 
1. To determine the effects of pv of the gonococcal LOS on the in vitro efficacy 
of a 2C7-epitope based vaccine. 
1.1. To create a set of isogenic mutants with defined LOS structures in a more 
virulent Ng strain such as MS11. 
1.2. To test the in vitro efficacy of murine mAb 2C7 against different LOS 
mutants created in this background. 
2. To determine the effectiveness of a chimeric mAb 2C7 (2C7-Ximab) 
engineered to enhance C’ activation in vitro and in vivo, and to investigate the 
role of pv of the gonococcal LOS in pathogenesis. 
2.1. To compare in vitro efficacies of two 2C7-Ximab constructs that differed in 
their ability to activate complement against the Ng LOS mutants. 
2.2. To test the effect of pv of the gonococcal LOS on Ng pathogenesis in 
vivo. 
2.3. To test the in vivo efficacy of the more potent (based on in vitro studies) 
2C7-Ximab against the four 2C7-positive Ng LOS mutants.  
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CHAPTER II 
Phase-variable heptose I glycan extensions modulate efficacy of 
2C7 vaccine antibody directed against Neisseria gonorrhoeae 
lipooligosaccharide 
 
 
 
 
 
 
 
 
(Originally published in The Journal of Immunology. Chakraborti, S., L. A. Lewis, 
A. D. Cox, F. St Michael, J. Li, P. A. Rice, and S. Ram. 2016. Phase-Variable 
Heptose I Glycan Extensions Modulate Efficacy of 2C7 Vaccine Antibody 
Directed against Neisseria gonorrhoeae Lipooligosaccharide. J Immunol 196: 
4576-4586. © [2016] The American Association of Immunologists, Inc.)  
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Abstract 
Neisseria gonorrhoeae, the causative agent of the sexually transmitted infection, 
gonorrhea, has developed resistance to most conventional antibiotics. Safe and 
effective vaccines against gonorrhea are needed urgently. A candidate vaccine 
that targets a lipooligosaccharide (LOS) epitope recognized by monoclonal 
(mAb) 2C7 attenuates gonococcal burden in the mouse vaginal colonization 
model. Glycan extensions from the LOS core heptoses (HepI and HepII) are 
controlled by phase-variable LOS glycosyltransferase (lgt) genes; we sought to 
define how HepI glycan extensions affect mAb 2C7 function. Isogenic 
gonococcal mutants in which the lgt required for mAb 2C7 reactivity (lgtG) was 
genetically locked ‘ON’ and the lgt loci required for HepI variation (lgtA, lgtC and 
lgtD) were genetically locked ‘ON’ or ‘OFF’ in different combinations were 
created. We observed 100% complement-dependent killing by mAb 2C7 of a 
mutant that expressed lactose (Gal-Glc) from HepI, while a mutant that 
expressed Gal-Gal-Glc-HepI fully resisted killing (>100% survival). Mutants that 
elaborated 4- (Gal-GlcNAc-Gal-Glc-HepI) and 5-glycan (GalNAc-Gal-GlcNAc-
Gal-Glc-HepI) structures displayed ‘intermediate’ phenotypes (<50% killing with 2 
µg/mL and >95% killing with 4 µg/mL of mAb 2C7). The contrasting phenotypes 
of the lactose-HepI and the Gal-Gal-Glc-HepI LOS structures were recapitulated 
with phase-variants of a recently isolated clinical strain. Despite lack of killing of 
the Gal-Gal-Glc-HepI mutants, mAb 2C7 deposited sufficient C3 on these 
bacteria for opsonophagocytic killing by human neutrophils. In conclusion, mAb 
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2C7 showed functional activity against all gonococcal HepI LOS structures 
defined by various lgtA/C/D ‘ON/OFF’ combinations, thereby providing further 
impetus for use of the 2C7 epitope in a gonococcal vaccine.  
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Introduction 
Gonorrhea, caused by the gram-negative diplococcus Neisseria gonorrhoeae 
(the gonococcus) is the most common bacterial sexually transmitted infection 
(STI) worldwide (2nd most common in the US). While most cases result in 
‘uncomplicated’ infections of the lower genital tract (urethritis in men and 
cervicitis in women), gonorrhea may sometimes lead to complications such as 
pelvic inflammatory disease and disseminated gonococcal infection. Serious 
sequelae of gonorrhea include infertility and ectopic pregnancy. Infected 
individuals who are asymptomatic or minimally symptomatic constitute an 
important reservoir for the transmission of infection. 
Globally, about 78 million new cases of gonorrhea occur annually (131). As a 
result of the emergence of antibiotic resistant strains, including strains resistant 
to third-generation cephalosporins such as cefixime and ceftriaxone (39) and the 
lack of vaccines (67, 132) or novel anti-infective therapeutics, gonorrhea has 
become a major public health concern. A safe and effective vaccine would be a 
key step in curbing the spread of multidrug-resistant gonorrhea. 
An obstacle to gonococcal vaccine development is the wide antigenic variation 
and/or variable expression of antigens that may elicit a protective response (e.g., 
pilin, opacity proteins, porin (Por) B, lipooligosacharides [LOS(s)]) (67, 132, 133). 
In addition, certain conserved antigens elicit non-protective, and in some 
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instances subversive responses; an example of the latter is Reduction modifiable 
protein (Rmp) (134). 
Despite its phase-variable nature (135), gonococcal LOS has been considered 
as a potential vaccine antigen (85, 136). Men who were experimentally infected 
with N. gonorrhoeae were less likely to become infected upon re-challenge if they 
elicited an anti-LOS IgG response following the initial infection (137). Previous 
work by our group identified an epitope on gonococcal LOS that is recognized by 
a monoclonal antibody (mAb) called 2C7 (and therefore referred to as the ‘2C7 
epitope) and was expressed on 94% of gonococci (64 out of 68) recovered 
directly from human cervical secretions (138). Gonococcal infection in humans 
elicits an antibody response against the 2C7 epitope (138). Expression of a 
lactose residue from heptose (Hep) II is required for binding of mAb 2C7 (139). 
Addition of an α-linked Glc residue at the 3-position of HepII represents the first 
step in synthesis of the lactose extension from HepII and is mediated by the 
phase-variable LOS glycosyltransferase G (lgtG) (140). 
Expression of lgtG is important for murine infection (70). Passive administration 
of mAb 2C7, as well as active immunization with a peptide mimic (mimitope) of 
the 2C7 epitope that was configured as a ‘multi-antigen peptide’ on a poly-lysine 
‘backbone’ significantly shortened the duration and burden of infection in the 
murine vaginal colonization model of gonorrhea (70). Taken together, these data 
 
42 
suggest that the 2C7 epitope represents a promising gonococcal vaccine 
candidate. 
Phase variation of LOS glycan extensions is mediated by slipped-strand 
mispairing at homopolymeric tracts within the coding regions of the lgt genes; 
lgtA, lgtC, lgtD modify glycan extensions from HepI; lgtG permits glycan 
extensions from HepII, as discussed above. Phase variation permits gonococci to 
express several distinct LOS structures that differ in their glycan composition 
(135, 141). Modulation of mAb 2C7 function by variations in HepI glycans has not 
been studied, is an important consideration that may impact the efficacy of a 2C7 
epitope-based vaccine and forms the basis of this study.  
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Materials and Methods 
Bacterial strains and culture conditions 
The Neisserial strains used in this study are described in Table 1. N. 
gonorrhoeae MS11 4/3/1 is a variant of MS11 VD300 with an IPTG inducible pilE 
that controls pilus expression (142). UMNJ60_06UM was recovered in 2013 from 
a symptomatic male with urethritis in Nanjing, PRC (143), and shows 
intermediate resistance to ceftriaxone (Etest MIC = 0.38 µg/mL and disc = 35 mm 
(sensitive ≥ 35mm). UMNJ60_06UM belongs to NG-MAST sequence type (ST) 
3289 and MLST ST 1600. 
Gonococcal strains were routinely cultured at 37°C in an atmosphere of 5% CO2 
on chocolate agar enriched with a chemically defined supplement (termed 
Isovitalex) used as an additive for cultivation of nutritionally fastidious 
microorganisms. For growth in liquid culture Morse A supplemented with Morse B 
and isovitalex were used (144). When used, antibiotics were added to GC agar 
plates at the following concentrations: erythromycin (Erm) 5 µg/mL, kanamycin 
(Kan) 100 µg/mL and streptomycin (Sm) 10 mg/mL. To induce pilus expression 
and enable transformation, strain MS11 4/3/1 was cultured on GC agar plates 
supplemented with 0.25 mM isopropyl-β-D-thiogalactopyranoside (IPTG). 
E. coli Top10, XL-10 gold and INVαF′ (Invitrogen) were cultured on LB agar 
supplemented, as needed, with antibiotics at the following concentrations; 
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ampicillin (125 µg/mL), Kan (50 µg/mL), Erm (400 µg/mL) or Sm (50 µg/mL). 
INVαF′, a naturally streptomycin sensitive strain, was used for propagation of all 
plasmids containing the ErmR-SmS streptomycin sensitivity cassette. 
Construction of mutants 
We created eight LOS mutants in MS11 4/3/1 (Table 1), in which expression of 
the four phase-variable lgt genes (lgtG, lgtA, lgtC and lgtD [shown schematically 
in Fig. 1A]) was genetically fixed either ‘ON’ or ‘OFF’ (or deleted). lgtG was 
insertionally inactivated (G- mutants; HepII unsubstituted) by amplifying lgtG::kan 
from FA19 lpt6A lptA lgtG (kindly provided by Dr. William Shafer, Emory 
University) using lgtG_F and lgtG_R primers (Supplemental Table S1), and 
subsequently transforming MS11 4/3/1 with the purified PCR product. The 
kanamycin marker in lgtG in FA19 was derived from pCK49 (145). Inactivation of 
lgtG in kanamycin resistant MS11 transformants was confirmed by PCR and 
DNA sequencing. 
lgtG was fixed ‘ON’ (G+ mutants; HepII substituted with lactose) by first 
exchanging the wild type lgtG with lgtG containing the ermC′-rpsLF62 cassette 
(pRYGW2ES1; Supplemental Table S2) that encodes resistance to Erm and 
sensitivity to Sm (146). Erm-resistant transformants were subsequently 
transformed with an lgtG - ‘ON’ construct (plgtG+; Supplemental Table S2) in 
which the C11 homopolymer had been changed to the non-phase variable 
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sequence CCCCTCCGCCA. lgtG-‘ON’ (G+) mutants were selected for resistance 
to streptomycin and screened for sensitivity to erythromycin (146). 
HepI glycan mutants were made in both the MS11 G+ and G- backgrounds, by 
first exchanging each of the three phase variable HepI lgt genes (lgtA, lgtC, lgtD) 
with an ermC′-rpsLF62 cassette (plgtA-ES, plgtC-ES, plgtD-ES; Supplemental 
Table S2), followed by transformation with the respective locked ‘ON’ (plgtA-‘ON’, 
plgtC-‘ON’, plgtD-‘ON’; Supplemental Table S2), locked ‘OFF’ (plgtC-‘OFF’; 
Supplemental Table S2) or mutated (segment deleted) form of each gene (plgtA-
del and plgtD-del; Supplemental Table S2). 
To insert the ermC′-rpsLF62 cassette into each lgt, the homopolymeric phase 
variation sequence in each lgt was deleted and a SmaI restriction site was 
incorporated by overlap extension PCR (using the respective F-Ext / R-Int and F-
Int / R-Ext primers; Supplemental Table S1). Each mutated (homopolymer 
deleted and SmaI incorporated)) lgt was amplified (F-Ext and R-Ext; 
Supplemental Table S1) and cloned (separately) into pCR2.1 TOPO TA 
(Invitrogen, USA). The ermC’-rpsLF62 cassette was extracted from pFLOB4300 
(provided by Dr. Janne G. Cannon, University of North Carolina, Chapel Hill) with 
PvuII and inserted into the SmaI site of each phase variable HepI lgt gene (See 
plasmids plgtA-ES, plgtC-ES and plgtD-ES; Supplemental Table S2). Plasmids 
carrying ermC’-rpsLF62 were maintained in the streptomycin sensitive E. coli 
INVαF′ (Life Technologies, USA). 
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Wildtype lgtA, lgtC and lgtD were amplified from MS11 4/3/1 chromosomal DNA 
by PCR using the corresponding F-Ext and R-Ext primers (Supplemental Table 
S1) and the amplicons ligated with pCR2.1 TOPO TA cloning vector (Life 
Technologies, USA) and transformed into chemically competent E. coli TOP10 
(Life Technologies, USA) per the manufacturer’s instructions (Supplemental 
Table S2). Plasmids with lgtA, lgtC and lgtD locked ‘ON’ and lgtC locked ‘OFF’ 
were generated using Quick Change Lightning Multi Site-Directed Mutagenesis 
kit (Agilent Technologies, USA) with the corresponding mutagenic primers 
(Supplemental Table S1) and transformed into chemically competent XL-10 Gold 
E. coli cells as per manufacturer’s recommendations (Supplemental Table S2). 
Double digestion and subsequent ligation of plasmids with wild type lgtA and lgtD 
with BbsI and SspI, and NotI and SpeI respectively, yielded plasmids with 
deletion mutations in lgtA and lgtD (Supplemental Table S2).  
Replacement of the lgtC-locked ‘ON’ gene in the mutant that expressed the 3-
Hex HepI/lgtG+ LOS structure with lgtC locked- ‘OFF’ yielded the 2-Hex-
HepI/lgtG+ mutant. Conversely, locking lgtC ‘ON’ in the 2-Hex-HepI/lgtG+ mutant 
yielded a lgtG+ mutant that expressed 3-Hex from HepI. 
UMNJ60_06UM lgtA::kan was constructed as previously described (147). 
Inactivation of lgtA was confirmed by PCR and western blot using mAb 3F11 
(mAb 3F11 described below). UMNJ60_06UM lgtA::kan 2-Hex and 
UMNJ60_06UM lgtA::kan 3-Hex were identified by western blot; UMNJ60_06UM 
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lgtA::kan 2-Hex reacted with mAb L8 but not mAb L1 (both mAbs are described 
below) and UMNJ60_06UM lgtA::kan 3-Hex reacted with mAb L1 (recognizes the 
globotriose Galα1,4-Galβ1,4-Glc structure, also called the PK-like structure) but 
not mAb L8 (data not shown). All UMNJ60_06UM strains reacted with mAb 2C7 
by western blot (data not shown) and by flow cytometry (see Results).  
Mass spectrometry 
Fresh chocolate agar plates were inoculated with bacteria harvested from 
cultures grown overnight for 15 h and bacteria were grown for 6 h. LOS was 
extracted, de-O-acylated and analyzed by MS as described previously (148). 
Antibodies 
Anti-LOS mAbs 2-1-L8 (henceforth referred to as mAb L8) (149), 17-1-L1 
(referred to as mAb L1) (150), 3F11 (151) and 2C7 (138) have been described 
previously. A schematic of the epitopes recognized by these mAbs is provided in 
Fig. 1. mAb 2C7 was purified from tissue culture supernatants over protein A/G 
(Pierce). Affinity-isolated goat anti-human factor H (FH) was prepared from anti-
FH antiserum (Complement Technology, Inc., Tyler, TX) by passage over FH-
sepharose as described previously (152). Alkaline phosphatase conjugated anti-
mouse IgG and anti-mouse IgM, and FITC-conjugated anti-mouse IgG and anti-
goat IgG were from Sigma. mAb 104 that binds to domains 1 and 2 of the α chain 
of human C4b-binding protein (C4BP) (153) was provided by Dr. Anna M. Blom 
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(Lund University, Malmö, Sweden). mAb 104 blocks C4BP function (153) and 
also blocks C4BP binding to gonococcal PorB (154) when pre-incubated with 
serum. However, mAb 104 does not displace C4BP already bound to the 
gonococcal surface and was used as the detection reagent for C4BP binding, as 
previously described (154). C3 deposited on gonococci was detected with FITC-
conjugated anti-human C3c (AbD Serotec / Bio-Rad), which detects both C3b as 
well as iC3b, at a dilution of 1:100. In order to demonstrate that mAb 104 blocked 
C4BP binding to bacteria, complement was incubated with mAb 104 (9 µg of 
mAb 104 was added to 30 µl of complement) on ice for 10 min, added to 
bacteria. C4BP bound to bacteria was detected with anti-human C4BP mAb 67 
(provided by Dr. Anna M. Blom) that recognizes domain 4 of the α chain of 
C4BP, followed by anti-mouse IgG A647 (Sigma) both at a dilution of 1:100. 
SDS-PAGE and western blotting 
Protease K-digested bacterial lysates were separated on 12% Bis-Tris gels 
(Invitrogen) with MES running buffer (Invitrogen) and LOS was visualized by 
Silver Stain (Bio-Rad). LOS was transferred to PVDF (Millipore) by western 
blotting; membranes were blocked with PBS/1% milk for 1 h at 37 °C and probed 
with tissue culture supernatants containing anti-LOS mAbs 2C7, 3F11, L1 and L8 
(described above) for 15 h at 4 °C, as described previously (155). mAb-reactive 
LOS bands were visualized with anti-mouse IgG-alkaline phosphatase (for mAbs 
2C7, L1 and L8) or anti-mouse IgM alkaline phosphatase (for mAb 3F11). 
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Hexosaminidase treatment 
To ascertain whether a terminal hexosamine (in this instance, GalNAc) was 
present on the lgtD-‘ON’ (D+) mutants, bacteria were suspended in water, frozen 
at -20 °C and thawed at 37 °C to osmotically lyse them and treated with 10 U 
DNAse I in DNAse buffer (Ambion) for 60 min at 37 °C. Treatment with DNAse I 
was carried out to reduce viscosity of the sample prior to electrophoresis. 
Proteins were digested with 1 mg/mL protease K (Calbiochem) in SDS (final 
concentration 0.01%) for 1 h at 50 °C. Protease K activity was destroyed by 
heating at 100 °C for 20 min. Terminal N-acetyl hexosamine from LOS was 
released by treating the sample with 30 U β-N-acetylhexosaminidase in G2 buffer 
(both from New England Biolabs) for 15 h at 37 ° C. Samples were 
electrophoresed on a 16.5% Criterion™ Tricine gel (Bio-Rad) at 100 V at 4 °C 
and LOS was visualized with silver staining as described above. 
Human complement 
Blood was obtained from human volunteers (informed consent approved by the 
University of Massachusetts Institutional Review Board) and serum 
immunodepleted of IgG and IgM by passage over Protein A/G plus agarose 
(Pierce, USA) and anti-human IgM agarose columns (Sigma) to prepare 
complement (156). The flow through was spin concentrated, equilibrated with 
PBS/0.1 mM EDTA and sterilized by passage through a 0.22 μm filter (Millipore, 
USA). Hemolytic activity was determined using the Total Haemolytic 
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Complement Kit (Binding Site, UK). Flow cytometry using FITC-conjugated anti-
human IgG and anti-human IgM (Sigma) showed no detectable IgG or IgM 
binding in the depleted serum to strains that were used in experiments. Antibody 
depleted serum (henceforth referred to as “complement” or C′) was aliquoted and 
stored at -80 °C until use. In some experiments C4BP function and binding to 
gonococci was blocked by adding mAb 104 (154, 157) to complement (30 µg of 
mAb 104/100 µL of complement). 
Flow cytometry 
Flow cytometry was used to measure binding of mAb 2C7, C4b-binding protein 
(C4BP) and deposition of complement C3 to bacteria as described previously 
(158-160). All Abs were diluted in Hanks Balanced Salt Solution containing 2 mM 
each of Ca2+ and Mg2+ (HBSS++). Data were collected from a BD LSRII or 
FACSCalibur instrument (BD Biosciences, Franklin Lakes, NJ) and analyzed 
using a FlowJo analysis software program (version 7.2.5; Tree Star, Ashland, 
MA). 
Serum bactericidal assays 
Serum bactericidal assays were performed as described previously (144, 155). 
Briefly, bacteria harvested from an overnight culture on chocolate agar plates 
were re-passaged onto fresh chocolate agar and grown for 6 h at 37°C in an 
atmosphere of 5% CO2. Approximately 2000 CFU gonococci in HBSS++ were 
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incubated with complement (concentration specified for each experiment) either 
in the presence or absence of mAb 2C7 (concentration specified for each 
experiment). In some experiments, C4BP function was blocked by pre-incubating 
complement with 30 µg/mL of mAb 104 as described above. Final bactericidal 
reaction volumes were maintained at 150 μL. Aliquots of 10 μL were plated onto 
chocolate agar plates in duplicate at the beginning of the assay (t0) and again 
after incubation at 37°C for 30 min (t30). Survival was calculated as the number of 
viable colonies at t30 relative to t0. 
Opsonophagocytosis assay using human PMNs 
Human neutrophils were isolated from human blood over a Percoll gradient and 
opsonophagocytosis assays performed using freshly isolated IL-8 primed 
adherent neutrophils as previously described (161). Briefly, bacteria were 
incubated with mAb 2C7 (4 µg/mL) and/or human complement (20%), or with 
HBSS++ alone (controls) for 15 min at 37 °C to permit IgG binding and C3 
deposition. Reaction mixtures were added to IL-8 primed, adherent PMNs at an 
MOI of 1:1 and centrifuged at 400 g for 4 min at 10 °C to achieve synchronous 
infection (161). Cells were washed once with PBS/0.5% BSA, placed into RPMI 
with 10% heat-inactivated FBS and warmed to 37 °C. Cells were washed and 
lysed using 1% saponin in PBS at 0 min (taken immediately after the 10 °C 
centrifugation step) and parallel wells were similarly treated at 60 min, serially 
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diluted in GC broth and plated to determine viable CFU. Survival was expressed 
as the percent of CFU at 60 min relative to CFU at 0 min. 
Statistical analysis 
Comparisons between two groups were made using the two-tailed unpaired t 
test. One-way ANOVA was used to compare multiple groups; pairwise 
comparisons were made by Tukey’s post-hoc test, while comparisons with a 
control group were made by Dunnett’s test. Two-way ANOVA was employed to 
compare groups when time or concentrations were independent variables.  
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Results 
Characterization of the LOS of the mutant strains 
A schematic of potential gonococcal LOS structures, the relevant enzymes 
involved in biosynthesis of the outer core and the specificity of anti-LOS mAb(s) 
used to characterize LOS glycan extensions are shown in Fig. 1A. Phase 
variable expression of lgtA, C and D leads to variation in the HepI glycan 
extensions; HepI 2-Hex (lgtA, C and D all ‘OFF’), HepI 3-Hex (lgtA ‘OFF’, lgtC 
‘ON’ and lgtD ‘ON’ or ‘OFF’; expression of lgtD is extraneous in an lgtA ‘OFF’ 
background), HepI 4-Hex (lgtA ‘ON’, lgtC and D ‘OFF’) and HepI 5-Hex (lgtA and 
D ‘ON’, lgtC ‘OFF’). Phase variable expression of lgtG controls expression of 
lactose on HepII. To investigate the role of HepI glycan extensions on the 
function of mAb 2C7, we constructed a series of mutants in the background of 
MS11 4/3/1 in which the phase variable lgt loci (lgtA, C, D and G) were 
genetically fixed either ‘ON’ or ‘OFF’. Lgt loci were fixed ‘ON’ by mutating the 
repetitive homopolymeric sequence found in each gene such that the 
homopolymer was removed but the coding sequence was not altered, as 
previously described (162). Lgt loci were fixed ‘OFF’ by deletion (lgtA, lgtD), 
insertional inactivation (lgtG) or by removing the homopolymeric sequence and 
inserting stop codons in all three reading frames (lgtC). 
The LOS structures expressed by individual mutants were characterized by 
western blotting using the anti LOS mAbs described in Fig. 1A; relative masses 
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of the LOS(s) were determined by SDS-PAGE (Fig. 1B). For simplicity, we refer 
to the mutants used in this study by their longest predicted HepI structures 
assuming activity of all expressed Lgt enzymes. The ‘ON’ and ‘OFF’ status of 
lgtG is indicated as G+ and G-, respectively. For example, in lane 1 (Fig. 1B), the 
mutant with lgtA and lgtD ‘ON’ is expected to have a 5-Hex HepI structure (note 
the use ‘Hex’ in the text includes both hexoses and N-acetyl hexosamines). lgtG 
in this mutant is fixed ‘ON’, so the mutant is referred to as 5-Hex/G+. This 
simplified designation for each mutant is provided at the bottom of Fig. 1B and in 
Table 1. 
Note that fixing an lgt ‘ON’ does not ensure that all of the LOS displayed on the 
bacterial surface will be substituted with the glycan added only by the encoded 
lgt enzyme(s) because transport of ‘incomplete’ LOS molecules to the outer 
membrane from the site of assembly on the cytoplasmic side of the inner 
membrane may occur prior to the addition of a glycan by all Lgt(s) that are fixed 
‘ON’. The amount and efficiency of each lgt enzyme will determine the ratio of 
‘complete’ to ‘incomplete’ LOS expressed (163). An example of the transport of 
‘incomplete’ LOS, shows that >50% of the LOS expressed by the two strains in 
which lgtD has been locked ‘ON’ (5-Hex/G+ and 5-Hex/G-) reacts with mAb 3F11 
and represent 4-Hex structures with a terminal lactosamine (the lower, more 
prominent band in lanes 1 and 2 shown in the Silver stain row; Fig. 1B) indicating 
that, despite expression of lgtD, the majority of LOS in these mutants is exported 
to the surface prior to the addition of the terminal GalNAc to LOS. Another 
 
55 
example is provided by mAb L8, which reacts specifically with LOS structures 
that contain a lactose on HepI and no glycans from the 3-position of HepII (i.e., 
lgtA ‘OFF’ and lgtG ‘OFF’ respectively) (149). Thus, if all the LOS(s) expressed 
by mutants with lgtA ‘OFF’ and lgtC and/or lgtG ‘ON’ were substituted with a 
terminal α(1,4)-linked Gal on HepI and/or a proximal Glc on HepII, these mutants 
should not react with mAb L8. In fact, mAb L8 reacted with all three mutants that 
had lgtA ‘OFF’ and lgtC and/or lgtG ‘ON’ (lanes 5, 6 and 7 in the L8 blot in Fig. 
1B), indicating export of LOS structures to the surface in these mutants prior to 
addition of: Glc on HepII by LgtG (lanes 5 and 7) and/or the distal α(1,4)-linked 
Gal on HepI (LgtC; lane 5). By contrast, fixing lgtA ‘ON’ (lgtA+) did not result in 
any detectable ‘short’ LOS structures (no L8 reactive bands seen in lanes 2 and 
4 (Fig. 1B; mutants with lgtA ‘ON’ and lgtG ‘OFF’), suggesting that LgtA efficiently 
added GlcNAc to the proximal lactose on HepI. 
Mass spectrometric analysis confirmed LOS(s) of HepII glycan extensions in the 
lgtG ‘OFF’ mutants and the presence of HepII glycans in the lgtG ‘ON’ mutants 
(Supplemental Table S3). Mass spectrometry also confirmed that all mutants 
expressed the expected HepI glycan extensions shown in Table 1, as well as 
‘incomplete’ structures as noted above. Further evidence that supported the 
presence of a terminal HexNAc residue in the 5-Hex/G+ and 5-Hex/G- mutants 
was provided by β-N-acetyl hexosaminidase treatment, which resulted in almost 
complete disappearance of the highest molecular mass band on silver staining of 
their LOS (Fig. 1C).  
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Figure 1. Characterization of the LOS of the MS11 mutants used in this study. A. 
Schematic representation of gonococcal LOS, relevant LOS glycosyltransferase 
(lgt) genes involved in its biosynthesis and the glycan structures recognized by 
anti-LOS mAbs. The four phase variable genes involved in glycan extensions 
lgtA, C, D and G are shown in black boxes. Specific structural requirements for 
binding of each of the four anti-LOS mAbs are indicated below the figure. B. 
Phenotypic characterization of the LOS mutants. Proteinase K-treated bacterial 
lysates were separated on 12% Bis-Tris gels and subsequently either stained 
with silver or transferred to PVDF by Western blotting and probed with specific 
anti-LOS mAbs. The genotypes of the mutants are indicated above the silver 
stain, while the simplified nomenclature for each of the mutants is indicated 
below the mAb L8 western blot. C. β-N-acetyl hexosaminidase treatment of 5-
Hex mutants results in loss of the highest molecular mass LOS species. Bacterial 
lysates were treated with β-N-acetyl hexosaminidase (lanes marked “+”) or buffer 
alone (lanes marked “-”) and LOS was separated on 16.5% Criterion™ Tricine 
gel (Bio-Rad) and visualized by silver staining.  
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Table 1: Bacterial strains used in this study. 
Strain Expected LOS phenotype  Description Ref. 
MS11 4/3/1  LOS structure not defined  MS11 with an IPTG inducible 
pilE 
(142) 
Derivatives of MS11 4/3/1 
5-Hex/G+  GalNAc-Gal-GlcNAc-Gal-Glc-HepI 
Gal-Glc-HepII 
lgtA-ON A 
lgtD-ON B 
lgtC-OFF C 
lgtG-ON D 
This study 
5-Hex/G-  GalNAc-Gal-GlcNAc-Gal-Glc-HepI 
Unsubstituted HepII 
lgtA-ON A 
lgtD-ON B 
lgtC-OFF C 
lgtG::kan 
This study 
4-Hex/G+  Gal-GlcNAc-Gal-Glc-HepI 
Gal-Glc-HepII 
lgtA-ON A 
lgtD-del E 
lgtC-OFF C 
lgtG-ON D 
This study 
4-Hex/G-  Gal-GlcNAc-Gal-Glc-HepI 
Unsubstituted HepII 
lgtA-ON A 
lgtD-del E 
lgtC-OFF C 
lgtG::kan 
This study 
3-Hex/G+  Gal-Gal-Glc-HepI 
Gal-Glc-HepII 
 
lgtA-del F  
lgtC-ON G 
lgtG-ON D 
This study 
3-Hex/G-  Gal-Gal-Glc-HepI 
Unsubstituted HepII 
lgtA-del F 
lgtC-ON G 
lgtG::kan 
This study 
2-Hex/G+  Gal-Glc-HepI 
Gal-Glc-HepII 
lgtA-del F 
lgtC-OFF C 
lgtG-ON D 
This study 
2-Hex/G-  Gal-Glc-HepI 
Unsubstituted HepII 
lgtA-del F 
lgtC-OFF C 
lgtG::kan 
This study 
2 → 3-Hex/G+  Gal-Gal-Glc-HepI; 
Gal-Glc-HepII 
2-Hex/G+ with lgtC-ON G This study 
3 → 2-Hex/G+  Gal-Glc-HepI 
Gal-Glc-HepII 
3-Hex/G+ with lgtC-OFF C  This study 
UMNJ60_06UM  LOS structure not defined Nanjing, PRC 2013; symptomatic 
male with urethritis. Intermediate 
resistance to ceftriaxone (E-test 
MIC = 0.38 µg/ml and disc = 35 
mm (sensitive ≥ 35mm) 
(143) 
Derivatives of UMNJ60_06UM 
UMNJ60 2-Hex  Gal-Glc-HepI 
Gal-Glc-HepII 
UMNJ60_06UM lgtA::kan; 
expresses 2-Hex on HepI 
This study 
UMNJ60 3-Hex Gal-Gal-Glc-HepI 
Gal-Glc-HepII 
UMNJ60_06UM lgtA::kan; 
expresses 3-Hex on HepI 
This study 
A lgtA-ON; G12 → GGGCGGAGGTGG 
B lgtD-ON; G13 → GGGCGGAGGTG 
C lgtC-OFF; G14 → GGTGAGGGGGGGGG  
D lgtG-ON; C11 → CCCCTCCGCCA 
E lgtD-del; 744 base pair (64 – 808 of coding sequence) deletion from lgtD  
F lgtA-del; 417 base pair (50 – 467 of coding sequence) deletion from lgtA 
G lgtC-ON; G14 → GGGGCGGAGG  
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HepI glycan substitutions modulate binding of mAb 2C7 
Binding of mAb 2C7 (concentrations ranging from 0.1 to 10 µg/mL) to the LOS 
mutants was studied by flow cytometry (FCM). The amount of mAb 2C7 bound to 
bacteria measured by FCM varied across the mutants (Fig. 2). The 2-Hex/G+ 
mutant showed maximum binding and 3-Hex/G+ the least; 4- and 5-Hex/G+ 
mutants bound ‘intermediate’ amounts of 2C7. Binding of mAb 2C7 requires 
lactose extension from HepII. As expected, none of the lgtG deletion (“G-”) 
mutants showed binding above conjugate control levels (data not shown).  
 
60 
Figure 2. HepI LOS glycan extensions modulate binding of mAb 2C7. The LOS 
mutants were incubated at 37 °C with increasing concentrations of mAb 2C7 for 
30 minutes. Surface-bound mAb 2C7 was detected by flow cytometry (FCM) 
using FITC-conjugated anti-mouse IgG. A. Binding of mAb 2C7 (concentrations 
ranging from 0.1 to 10 µg/ml) to LOS mutants. Each data point represents the 
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mean of the median fluorescence intensities of 3 separate experiments (±SEM). 
Comparisons between the mutants at each dilution of mAb 2C7 were performed 
by two-way ANOVA with Tukey’s post-test. ***, P<0.001 for the 2-Hex/G+ versus 
all other mutants at each of the five concentrations tested. **, P<0.01 for the 3-
Hex/G+ mutant versus the 4- and 5-Hex/G+ mutants at the three concentrations 
indicated. Overall P values for interaction, row factor and column factors were all 
<0.0001. B. Representative histograms depicting mAb 2C7 binding at 0.1, 1.0 
and 10 µg/mL. X-axis, fluorescence on a log10 scale; Y-axis, counts.  
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HepI glycan extensions modulate bactericidal efficacy of mAb 2C7 
The ability of mAb 2C7 to kill each of the four G+ mutants was studied next. 
Bacteria were incubated with either 2 µg/mL or 4 µg/mL of mAb 2C7 and 20% 
human complement (normal human serum depleted of IgG and IgM); survival at 
30 min was measured by bacterial CFU relative to CFU at 0 min (Fig. 3). As 
expected, control reactions (no mAb 2C7 added) showed no killing (>100% 
survival). Additional controls with mAb 2C7 alone (no added complement) or 
heat-inactivated complement also showed no killing (data not shown). The 2-
Hex/G+ mutant showed >90% killing in the presence of 2 µg/mL of mAb 2C7; the 
3-Hex/G+ mutant was fully resistant (>100% survival) to 4 µg/mL of mAb 2C7. 
The 4-Hex/G+ and 5-Hex/G+ mutants showed an intermediate pattern – i.e., 
resistance (≥ 50% survival) to 2 µg/mL of 2C7, but sensitivity (<50% survival) to 4 
µg/mL of 2C7 (in this instance, >90% killing was observed). The bactericidal data 
followed a hierarchy similar to that seen with mAb 2C7 binding (Fig. 2). 
Binding of the classical pathway inhibitor C4b-binding protein (C4BP) to 
gonococci modulates the efficacy of mAb 2C7 (155) and could have contributed 
to differences in susceptibility to mAb 2C7. We measured binding of C4BP to the 
four G+ mutants using heat-inactivated serum as a source of C4BP and found 
that all G+ mutants bound high and similar amounts of C4BP (Supplemental Fig. 
S1). These findings are consistent with prior data showing that MS11 and its LOS 
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derivatives that expressed at least 2 hexoses from HepI bound C4BP well (154, 
164). 
The gonococcal genome contains over 100 phase variable genes. To confirm 
that differences in the binding of mAb 2C7 and killing between the 3-Hex/G+ and 
2-Hex/G+ mutants were specifically related to LOS structure; lgtC was fixed ‘ON’ 
in the 2-Hex/G+ strain permitting addition of Gal-α(1,4) to HepI (strain designated 
as 2→3-Hex/G+) and lgtC was fixed ‘OFF’ in the 3-Hex/G+ strain, which blocked 
addition of Gal-α(1,4) to HepI (strain designated as 3→2-Hex/G+). The LOSs 
expressed by the mutants were verified by silver staining and with western blots 
using mAbs L8 and L1 (Fig. 4A). The two mutants, 2→3-Hex/G+ and 3→2-
Hex/G+, were next examined for their ability to bind and be killed by mAb 2C7 
(Fig. 4B and 4C). The results recapitulated those seen with the 3-Hex/G+ and 2-
Hex/G+ mutants, respectively.  
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Figure 3. HepI glycan extensions affect C’-dependent bactericidal activity by 
mAb 2C7. Each mutant was incubated with 20% (v/v) human complement (C′) in 
HBSS++ at 37 °C for 30 minutes either in the absence of or presence of 2 or 4 
µg/mL mAb 2C7. Percent survival was calculated as the number of CFU at 30 
min relative to the number of CFU at 0 min. Each bar represents the percent 
survival (mean of 3 independent experiments ±SEM). Comparisons among the 
mutants at each of the mAb 2C7 concentrations tested were made by two-way 
ANOVA and pairwise comparisons were made with Tukey’s post-hoc analysis. 
Overall P values for interaction, row factor and column factors were all <0.0001. 
*, P<0.05; **, P<0.01; ***, P<0.001; ****, P<0.0001.  
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Figure 4. Confirmation of extreme 
mAb 2C7 binding phenotypes. Genetic 
conversion of MS11 2-Hex/G+ to 3-
Hex/G+ (2→3-Hex/G+) and 3-Hex/G+ 
to 2-Hex/G+ (3→2-Hex/G+) confirms 
decreased binding mAb 2C7 and 
increased resistance of 3-Hex/G+ to 
mAb 2C7-mediated complement-
dependent killing. A. Verification of 
LOS expression by the mutants by 
silver staining and western blotting with 
mAbs L1 and L8. B. mAb 2C7 (4 
µg/ml) binding to the 2- and 3-Hex 
‘conversion’ mutants. mAb 2C7 binding 
was performed by FCM as described in 
Fig. 2. Each bar represents the mean 
(±SEM) of three independent 
experiments. An unpaired two-tailed t-
test was used to compare the mutant 
pairs. C. Susceptibility of the 2- and 3-
Hex ‘conversion’ mutants. Serum 
bactericidal assays were performed as 
described in Fig. 3 in the presence of 4 
µg/mL of mAb 2C7 and 20% human 
complement. Each bar represents the 
mean (±SEM) of three independent 
experiments. An unpaired two-tailed t-
test was used to compare the mutant 
pairs. **, P<0.01; ***, P<0.001.  
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Serum resistance of 3-Hex/G+ is overcome by increasing complement 
concentrations or blocking C4BP binding 
We next asked whether serum resistance of the 3-Hex/G+ mutant could be 
overcome by either increasing complement concentrations or by blocking C4BP 
binding to bacteria. As shown in Fig. 5A, in the presence of 4 µg/ml of 2C7, killing 
of 3-Hex/G+ was enhanced in a dose dependent manner by increasing the 
concentration of complement. Complement alone (mAb 2C7 absent), even at the 
highest concentration tested (70%), did not result in killing. Similar to our prior 
observations with strain MS11 (154), mAb 104 blocked C4BP binding to the 3-
Hex/G+ mutant (Fig. 5B), which resulted in enhanced killing by mAb 2C7 
compared to control reactions that lacked mAb 104 (Fig. 5C). Thus, increasing 
complement activation on the 3-Hex/G+ mutant either by increasing the 
concentration of complement or by decreasing complement inhibition by C4BP 
overcame its serum-resistant phenotype.  
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Figure 5. Serum 
resistance of MS11 3-
Hex/G+ can be 
overcome by 
increasing complement 
concentrations or by 
inhibiting C4BP binding 
to bacteria. A. 
Increasing complement 
concentrations 
enhances killing of the 
3-Hex/G+ mutant in a 
dose-dependent 
manner. The 3-Hex/G+ 
mutant was incubated 
with 4 µg/ml of mAb 
2C7 and increasing 
concentrations of 
human complement 
(C′; 30%, 50% and 
70%) and bactericidal 
assays were performed 
as described in Fig. 2. 
The control reaction 
contained only the 
highest concentration 
of C′ used (70%) 
without any added 
mAb 2C7. The Y-axis 
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shows percent survival. Each bar represents the mean (±SEM) of three 
independent experiments. Comparisons across different conditions of incubation 
were made by one-way ANOVA and pairwise comparisons were made with 
Tukey’s post-test. The overall P value for the ANOVA was 0.0002. B. mAb 104 
blocks C4BP binding to 3-Hex/G+. 3-Hex/G+ was incubated with either 20% C′ 
alone or 20% C′ plus mAb 104 (final concentration of 30 µg/ml in the reaction 
mixture). C4BP bound to bacteria was detected with anti-C4BP mAb 67 followed 
by anti-mouse IgG A647. X-axis, fluorescence on a log10 scale; Y-axis, counts. 
Numbers alongside histograms represents median fluorescence of the entire 
population and outlines or shading correspond to the histograms. C. Bactericidal 
efficacy of mAb 2C7 when C4BP binding to bacteria and function was blocked 
using mAb 104. C′ was incubated with anti-C4BP mAb 104 to a final 
concentration of 30 µg/ml at 4 °C for 15 min. The 3-Hex mutant was then 
incubated with (4 µg/ml or 10 µg/ml) or without mAb 2C7, followed by the 
addition of mAb 104-treated serum to a final concentration of 20%. Parallel 
control reactions included bacteria, mAb 2C7 and C′ (no added mAb 104). The Y-
axis denotes percent survival at 30 min. Comparisons between reactions that did 
or did not contain mAb 104 at each concentration of mAb 2C7 were made with a 
two-way ANOVA, with Sidak’s multiple comparison test. Overall P values for 
interaction, row factor and column factor were 0.009, 0.0009 and 0.0014, 
respectively. Each bar represents the mean (±SEM) of three independent 
experiments. *, P<0.05; **, P<0.01; ***, P<0.001.  
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mAb 2C7 enhances C3 deposition and facilitates opsonophagocytosis of 
the 3-Hex/G+ mutant 
C3 fragments, in particular iC3b deposited on bacteria enhance 
opsonophagocytosis. mAb 2C7 did not promote direct killing by complement of 
the 3-Hex/G+ mutant in serum bactericidal assays that used 20% complement 
(Fig. 3). However, we reasoned that mAb 2C7 mediated C3 deposition on the 3-
Hex/G+ mutant supports opsonophagocytic killing and constitutes a potential 
mechanism of protection by vaccine Ab. 
Total C3 (C3b and iC3b) deposition on the 3-Hex/G+ was measured by FCM; the 
three other G+ mutants were included as comparators. Bacteria were incubated 
with either 2 µg/ml or 4 µg/ml of mAb 2C7 and 20% complement; C3 deposited at 
15 and 30 min was measured. In the absence of mAb 2C7 there was minimal C3 
deposition on all mutants (median fluorescence <2-fold above baseline conjugate 
control levels [Fig. 6]). As expected, the 2-Hex/G+ mutant that was highly 
susceptible to complement-dependent killing showed the most rapid 
accumulation and the highest levels of C3 deposition. An intermediate amount of 
C3 was deposited on the 4-Hex mutant. The 3- and 5-Hex/G+ mutants bound the 
least; there was a trend toward less C3 on 3-Hex/G+ compared to 5-Hex/G+, 
however the differences were not significant. 
The opacity (Opa) proteins of N. gonorrhoeae encompass a phase-variable 
family of proteins (gonococci possess 11 opa genes and can express three or 
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four Opa proteins simultaneously (165) that can engage CEACAM3 on PMNs 
and mediate opsonophagocytic killing independent of antibody and complement 
(166, 167). To address the potential role of mAb 2C7-dependent complement 
activation in facilitating opsonophagocytosis of the 3-Hex/G+ mutant, we 
recreated the 3-Hex/G+ LOS structure in the background of an Opa-negative 
MS11 strain (168). The 3-Hex/G+ Opa-negative MS11 mutant strain bound 
similar (low) levels of mAb 2C7 and was fully resistant (>100% survival) to killing 
by 4 µg/ml of mAb 2C7 plus 20% complement (Fig. 7; bar at far left), analogous 
to the 3-Hex/G+ in MS11 with its native opa genes intact. In the presence of both 
mAb 2C7 and complement (bar to the extreme right), PMNs caused a 60% 
decrease in bacterial survival (P<0.01 compared to the control reaction with 
bacteria alone plus PMNs [second bar from left]). Compared to the control with 
bacteria and PMNs (second bar from left), reactions that contained bacteria, 
PMNs and 2C7 (third bar from the left) or bacteria, PMNs and complement 
(fourth bar from the left) did not show increased killing.  
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Figure 6. C3 deposition on the lgtG-‘ON’ (G+) HepI glycan LOS mutants. The 
four G+ LOS mutants with varying HepI glycan extensions were incubated with 
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20% C′ and 4 µg/ml mAb 2C7 in HBSS++ at 37 °C and total C3 (C3b and iC3b 
fragments) deposited on the bacterial surface at 15 or 30 min was measured by 
FCM with FITC-conjugated sheep anti-human C3c Ab (detects both C3b and 
iC3b). Control reactions included bacteria incubated with 20% C′ alone (no mAb 
2C7 present) for 15 and 30 min. The median fluorescence intensity was 
recorded. Similar C3 deposition was seen on bacteria incubated with C′ alone for 
15 min (not shown). Differences in C3 deposition across the mutants within each 
group was measured by two-way ANOVA and pairwise comparisons were made 
with Tukey’s post-test. The data represent the mean (±SEM) from three 
independent experiments. P values for interaction, row factor and column factors 
were all <0.0001. *, P<0.05; ****, P<0.0001. B. Representative histograms of a 
representative experiment in A is shown. X-axis, fluorescence on a log10 scale; 
Y-axis, counts.  
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Figure 7. mAb 2C7 
facilitates 
opsonophagocytosis 
of 3-Hex/G+ by 
PMNs. Freshly 
isolated IL-8 primed 
human PMNs 
adherent on plastic 
coverslips were 
synchronously 
infected with the 3-
Hex/G+ mutant that 
had been pre-
incubated with mAb 
2C7 (4 µg/ml) 
and/or C′ for 15 min 
37 °C at a MOI of 1. A reaction that contained bacteria, mAb 2C7 and C′ (no 
PMNs) was also included (bar closest to the Y-axis). Percent survival (CFU at 60 
min relative to CFU at 0 min) is shown on the Y-axis. Each bar represents the 
mean of the percent survival of 3 separate experiments (±SEM). A comparison of 
killing across the four groups that contained PMNs was performed by one-way 
ANOVA, with Dunnett’s post-test used to make comparisons with the control 
reaction (bacteria plus PMNs; second bar from left). The overall P value for the 
ANOVA was 0.0064. *, P<0.05; **, P<0.01.  
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Relative resistance of a 3-Hex/G+ expressing lgtC phase-variant of a 
clinical isolate to killing by mAb 2C7 
To ascertain if the decreased mAb 2C7 binding and increased resistance of the 
3-Hex/G+ mutant was generalizable and not unique to strain MS11 alone, we 
identified 2-Hex and 3-Hex phase variants of an lgtA mutant (ΔlgtA) of a 
minimally passaged clinical isolate called UMNJ60_O6UM. Two natural variants 
of UMNJ60_O6UM ΔlgtA were selected – one that expressed lactose on HepI 
(UMNJ60_O6UM 2-Hex; analogous with lgtC phase varied ‘OFF’ and therefore 
did not react with mAb L1) and one that expressed 3-Hex’ Pk-like LOS on HepI 
(UMNJ60_O6UM 3-Hex; analogous with lgtC phase varied ‘ON’ and therefore 
reacted with mAb L1; (169). Both variants had lgtG phase- ‘ON’ and therefore 
expressed lactose from HepII. The two variants were examined for mAb 2C7 
binding and killing in a complement-dependent bactericidal assay. 
UMNJ60_O6UM 2-Hex variant bound more mAb 2C7 than the UMNJ60_O6UM 
3-Hex variant (Fig. 8A). UMNJ60_O6UM 3-Hex was also more resistant to 
complement-dependent killing by mAb 2C7 (Fig. 8B). The 2-Hex variant was 
killed >99% and 100% by complement in the presence of 2 µg/ml and 4 µg/ml of 
2C7 respectively; the 3-Hex variant survived ~70% and ~50% under similar 
conditions. 
Unlike the MS11 3-Hex/G+ mutant that was fully resistant (>100% survival) to 
killing by even 4 µg/ml of mAb 2C7 plus 20% complement (Fig. 3), the 
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UMNJ60_O6UM 3-Hex variant was partly susceptible to killing under similar 
conditions. As noted above, C4BP binds to certain N. gonorrhoeae strains, 
including MS11, and promotes serum resistance (Ref. (154) and Supplemental 
Fig. S1). To determine if UMNJ60_O6UM bound C4BP, we compared C4BP 
binding to the two UMNJ60_O6UM LOS variants with the corresponding MS11 
LOS mutants. Both UMNJ60_O6UM variants bound significantly lower amounts 
of C4BP than the corresponding MS11 LOS mutants (Fig. 8C), thus providing a 
probable explanation for the greater sensitivity to complement of 
UMNJ60_O6UM variant 3-Hex compared to MS11 3-Hex/G+. Collectively, these 
data suggest that the 3-Hex HepI structure negatively affects mAb 2C7 binding 
and function.  
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Figure 8. Validation of the MS11 3-Hex/G+ phenotype with a 3-Hex/G+ phase 
variant of UMNJ60_06UM, a recent clinical isolate of N. gonorrhoeae. Phase 
variants of an lgtA mutant of UMNJ60_06UM that expressed 3-Hex HepI 
(UMNJ60 v. 2-Hex; lgtC ‘ON’, reacts with mAb L1, but not mAb L8) and that 
expressed 2-Hex HepI (UMNJ60 v. 3-Hex; lgtC ‘OFF’, reacted with mAb L8 but 
not mAb L1) were selected. Both strains reacted with mAb 2C7 (consistent with 
lgtG ‘ON’). A. The 3-Hex expressing variant of UMNJ60_06UM binds less 2C7 
than the 2-Hex expressing variant. Bacteria were incubated with mAb 2C7 (1 
µg/ml or 3.2 µg/ml) and bound mAb was detected by FCM as described in Figure 
2. The MS11 2-Hex/G+ and 3-Hex/G+ mutants were included as comparators. 
Each bar represents the mean of the median fluorescence intensities of 3 
independent experiments (±SEM). Comparisons between the HepI 2-Hex and 
HepI 3-Hex-expressing isolates were made by the unpaired two-tailed t-test. 
Histograms from a representative experiment are shown on the right of the bar 
graphs. B. A 3-Hex variant of UMNJ60_06UM is more resistant to killing by mAb 
2C7 than a 2-Hex variant. UMNJ60 v. 2-Hex and v. 3-Hex were incubated with 
increasing concentrations of mAb 2C7 (either 0, 2 or 4 µg/ml) plus 20% human 
complement and survival of bacteria at 30 min relative to CFU at time 0 min, was 
measured in serum bactericidal assays. Y-axis, percent survival. One-way 
ANOVA was used to compare killing of each of the variants at the different 
concentrations of mAb 2C7 tested; the v. 2-Hex and the v. 3-Hex groups were 
compared separately. The overall P values for the v. 2-Hex and v. 3-Hex groups 
were 0.0002 and 0.006, respectively. C. The HepI LOS phase-variants of 
UMNJ60_06UM are weak C4BP binders. UMNJ60 v. 2-Hex and UMNJ60 v. 3-
Hex were incubated with heat-inactivated NHS and C4BP bound to bacteria was 
detected by FCM. MS11 2-Hex/G+ and 3-Hex/G+ were included as comparators. 
The conjugate control (“Conj. cont.”) represents a reaction mixture that lacked 
serum. Each bar represents the mean of 3 independent experiments ±SEM. A 
two-tailed unpaired t-test was used to compare C4BP binding to the 2-Hex and 3-
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Hex expressing strain pairs. Histograms from a representative experiment are 
shown to the right of the bar graph. The X-axis shows fluorescence on a log10 
scale and the Y-axis the events. *, P<0.05; **, P<0.01; ***, P<0.001, ****, 
P<0.0001.  
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Discussion 
The role of LOS glycan extensions in the pathogenesis of N. gonorrhoeae, 
including their role in immune evasion, is well recognized. Much attention has 
been directed to LOS that expresses the lacto-N-neotetraose (LNnT) structure on 
HepI, which mimics host paraglobosides (170). Unsialylated LNnT interacts with 
the asialoglycoprotein receptor and facilitates adhesion of gonococci to male 
urethral epithelial cells (32). A lectin-like interaction between the terminal 
lactosamine residue of LNnT and gonococcal opacity proteins (Opa) plays a role 
in inter-gonococcal adhesion and the degree of colony opacity (171). Gonococci 
possess a surface-exposed LOS sialyltransferase (172) that catalyzes the 
transfer of N-acetylneuraminic acid (Neu5Ac) from the donor molecule CMP-
Neu5Ac present in host secretions (173, 174), on to the 3-position of the terminal 
Gal residue of LNnT. LNnT sialylation is involved in the inhibition of all three 
pathways of complement and enables gonococci to resist killing by natural 
IgG/IgM and complement in normal human serum (NHS), called serum 
resistance (83, 175, 176). Sialylation of gonococcal LNnT in vivo has been 
demonstrated by electron micrographs of organisms in human secretions (177). 
Schneider and colleagues also demonstrated the importance of phase variation 
of gonococcal LOS and LNnT sialylation in humans. They inoculated male 
volunteers intra-urethrally with a variant of strain MS11 that expressed a (non-
sialylated) 2-Hex HepI structure predominantly. At the onset of symptoms, 
several days later, almost all men shed bacteria that expressed LOS with 
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predominantly longer (including the 4-Hex HepI), sialylatable HepI structures 
(178). Recently, McLaughlin and colleagues found that gonococci present in 
urethral exudates of infected men displayed an lgt genotype that predicted 
sialylation of terminal lactosamine; lgtA was in-frame, while lgtC and lgtD were 
out-of-frame in most cases (179). The importance of LOS sialylation in 
pathogenesis has also been demonstrated in the mouse vaginal 
colonization/infection model; gonococcal mutants that lack LOS sialyltransferase 
(Lst) are outcompeted by their wild-type counterparts (158, 180). The efficacy of 
mAb 2C7 against phase variant and sialylated bacteria has been demonstrated 
both in vitro (organisms grown in media containing 2 µg/ml of CMP-Neu5Ac; 
(155)) and in vivo in mice, where LOS sialylation occurs (181)). 
Diversity of surface antigens generated by phase variation confers a survival 
advantage to microbes and enables them to adapt to different niches in the host. 
Phase-variation of LOS also modulates resistance of N. gonorrhoeae to killing by 
NHS, independent of LOS siaylation (182-184). Expression of GalNAc distal to 
LNnT (i.e., 5-Hex HepI; lgtA and lgtD ‘ON’) permits binding of natural IgM present 
in NHS (185) and enhances bacterial killing by complement (182). Although the 
terminal GalNAc enhances killing by NHS, gonococci that possess LOS with this 
terminal residue interact with macrophage galactose-type lectin (MGL) on 
dendritic cells. This may result in more pronounced Th2 and Th17 responses 
(186), instead of protective Th1 responses (67, 187). Expression of a truncated 
3.6 kDa LOS (the 2-Hex [lactosyl] HepI), which also is a host glycan mimic, is 
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also associated with increased resistance to NHS because most humans lack 
natural (IgG/IgM) Ab against this epitope (183). 
Our studies used mAb 2C7 and NHS depleted of IgG/IgM in bactericidal assays. 
In contrast to previous studies where mutants with short HepI glycan extensions 
(e.g., lgtA ‘OFF’) were more resistant to killing by NHS (182, 184), the 2-Hex/G+ 
mutant studied herein was more susceptible to killing by mAb 2C7 and 
complement (i.e., NHS depleted of IgG/IgM) than the three remaining mutants 
because it bound the most mAb 2C7, which resulted in overwhelming 
complement activation. By comparison, the 5-Hex/G+ strain, ordinarily more 
sensitive to killing by IgM in NHS (185), was relatively resistant to killing by mAb 
2C7 plus complement because it bound less mAb 2C7. We replicated previous 
studies and showed killing (100% killing in 10% serum [IgG and IgM intact]) of 
the 5-Hex/G+ mutant; the 2- and 3-Hex/G+ strains were fully serum resistant 
(>100% survival in 10% NHS). 
The 2C7 LOS epitope represents a promising vaccine candidate. Separately, we 
have shown that HepII glycan extension, required to generate the epitope, is also 
important in the mouse model of gonococcal colonization/infection, where an lgtG 
deletion mutant of strain FA1090 was shown to be less ‘fit’ (70). A role for HepII 
glycans in gonococcal pathogenesis is supported by the observation that >95% 
(96 of 101) of minimally passaged clinical isolates reacted with mAb 2C7 (138). A 
contemporary analysis of over 70 gonococcal isolates recovered from men with 
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urethritis attending an STD clinic in Nanjing, China, has substantiated these 
findings; all the recovered isolates bind mAb 2C7 (our unpublished observations). 
A potential reason for (2C7) vaccine resistance would be selection of LOS 
variants that show decreased binding of Ab. One explanation would be natural 
selection of variant(s) expressing LOS with lgtG ‘OFF’. However, loss of LgtG 
expression may reduce fitness and therefore not be favored (70). The hypothesis 
addressed in our study was that other different HepI LOS structures may affect 
binding and function of mAb 2C7, an important consideration in predicting 
vaccine efficacy and coverage.  Strains that expressed the Pk-like LOS structure 
(represented by the 3-Hex/G+ mutant) bound the least amount of mAb 2C7 and 
were relatively resistant to complement-mediated killing by mAb 2C7. With the 
exception of lgtC, which adds the terminal Gal on HepI of the 3-Hex/G+ mutant 
via an α-linkage, glycans added by enzymes encoded by the lgtABCDE operon 
are β-linked (182, 188-190). The α-linked terminal Gal on HepI of the 3-Hex/G+ 
may hinder access of mAb 2C7 to its epitope. 
Several microbes bind C4BP, an inhibitor of the classical pathway, to evade 
killing by complement (191). MS11 binds C4BP and mAb 2C7 must surmount 
this barrier to mediate killing through the membrane attack complex insertion. 
The inhibiting role of C4BP was evident when C4BP binding to bacteria and 
C4BP function were blocked using mAb 104 resulting in increased killing of 
bacteria. Moreover, the 3-Hex variant of a clinical strain that bound low levels of 
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C4BP (UMNJ60_06UM) was more susceptible to killing by mAb 2C7 than the 
MS11 3-Hex/G+ that binds high levels of C4BP. 
Despite the absence of killing through membrane attack complex, mAb 2C7 
deposited sufficient C3 on 3-Hex/G+ bacteria to enable human PMNs to 
decrease CFU by >50%. Of note, maximal opsonophagocytic killing by PMNs 
required both Ab and complement; either one alone did not result in killing above 
baseline levels when bacteria only were incubated with PMNs. The Neisserial Pk-
like LOS structure can also be sialylated (169, 192). Unlike sialylation of LNnT 
LOS, sialylation of Pk-like LOS does not enhance FH binding to bacteria and 
confers resistance to only low, but not high, concentrations of NHS (169). While 
McLaughlin and colleagues found that lgtC was out-of-frame in all 7 samples of 
N. gonorrhoeae obtained directly from male urethras (179), Mandrell reported 
that as many as 36 of 70 (51%) of strains surveyed in vitro bound mAb 3D9, 
which reacts with the Pk antigen (193). The advantage conferred by the 
gonococcal Pk-like LOS in vivo remains to be elucidated. 
How mAb 2C7 decreases gonococcal burden and duration of infection in vivo – 
i.e., the specific contributions of direct complement-mediated killing, 
opsonophagocytosis or other novel mechanism(s) of Ab-mediated clearance – 
remain to be elucidated. Notwithstanding the differences in direct killing of the 
mutants by mAb 2C7 and complement, enhanced C3 deposition occurred on all 
the HepI/G+ mutants; in particular, the 3-Hex/G+ mutant, which was not killed 
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directly, was opsonophagocytosed and killed. Our findings support the inclusion 
of the 2C7 LOS epitope in a vaccine candidate against N. gonorrhoeae.  
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Supplementary Materials 
Supplemental Table S1: Primers used in this study. 
Primers 5’-3’ Sequence 
lgtG_F CTATCTGTACGACGTTTTGAAAATTGC 
lgtG_R CCCCGTATTTAAAGGATAAAGGCAAAA 
lgtG530 CGCATTACCCTACCCCCTCACGCAC 
lgtG1729 TCTGTACGACGTTTTGAAAATTGC 
Lal-6 GCGACAGGGACGGGTTGTAGTTCAG 
Lal-7 GGCACGGAACGCTACACATTGGAT 
lgtA Fwd-Ext AGGCAATTTCCAAACTGCTTTGTCCGA 
lgtA Rev-Ext GTTTGGCGGTATTCTAGGCTGTCGAAC 
lgtC Fwd-Ext TATTTGAGCGGAGTGGAAAAAGCCTGC 
lgtC Rev-Ext ATCCAAGTTGCGCCAAGTCTGATTCAC 
lgtD Fwd-Ext TCAAAATGTCCTGCGAATGGGTGGAAC 
lgtD Rev-Ext AGCCAAGCTGATAACGTGGTTTTGCAT 
lgtA-On FwdA ATTGGCAAAGTCGGGCGGAGGTGGATATATTGCGCGC 
lgtA-On RevA GCGCGCAATATATCCACCTCCGCCCGACTTTGCCAAT 
lgtC-On FwdA CGCCAATTTGCGGGGCGGAGGTAATATCCGCTTT 
lgtC-On RevA AAAGCGGATATTACCTCCGCCCCGCAAATTGGCG 
lgtC-Off FwdA CCGCCAATTTGCGGTGAGGGGGGGGGTAATA 
lgtC-Off RevA TATTACCCCCCCCCTCACCGCAAATTGGCGG 
lgtD-On FwdA GAATTGGCAAAGTCGGGCGGAGGTGAATATATTGCGCGCAC 
lgtD-On RevA GTGCGCGCAATATATTCACCTCCGCCCGACTTTGCCAATTC 
lgtA Fwd-IntB AAAAGCGGGACAGCCGTATCAAAATCCCGGGATTGAGAAAATCGTGGGCGAGATGG 
lgtA Rev-IntB CCATCTCGCCCACGATTTTCTCAATCCCGGGATTTTGATACGGCTGTCCCGCTTTT 
lgtC Fwd-IntB GAGATGGACATCGTATTTGCGGCAGACCCCGGGCCTTATGGGATACCGATTTGGGCGGTA 
lgtC Rev-IntB TACCGCCCAAATCGGTATCCCATAAGGCCCGGGGTCTGCCGCAAATACGATGTCCATCTC 
lgtD Fwd-IntB GTGAATCAGACTTGGCGCAACTTGGATCCCGGGCATGAAGACATTGTCGCCGTTTTCCCT 
lgtD Rev-IntB AGGGAAAACGGCGACAATGTCTTCATGCCCGGGATCCAAGTTGCGCCAAGTCTGATTCAC 
AIndicates primers for mutagenesis; Single base substitutions are underlined in 
bold, consecutive bases underlined in italics span short deletions that render the 
sequence in frame for full length protein translation. 
BSmaI site – CCCGGG; Primer regions corresponding to the indicated lgt are 
indicated in bold, overlap regions are indicated in italics.  
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Supplemental Table 2: Plasmids used in this study. 
Plasmids Relevant characteristics and construction details 
pFLOB4270 
(146) 
Two-step mutagenesis system used to construct unmarked deletions or mutations. 
Contains an ErmR-SmS cassette that encodes resistance to Erm and sensitivity to Sm 
(rpsLF62). Used to construct unmarked mutations in lgtG, C, A and D. 
lgtG constructs 
pRYGW2 Contains wildtype lgtG from Ng strain 398079 amplified with primers lgtG530 and 
lgtG1729 in pCR2.1-TOPO (Invitrogen, Carlsbad, CA). Analogous to pRYGW1, 
described previously (70). Used to create pRYGW2ES1. 
pRYGW2ES1 pRYGW2 with the ErmR-SmS cassette that encodes resistance to Erm (ErmC) and 
sensitivity to Sm (rpsLF62) from pFLOB43002. The ErmR-SmS cassette was liberated 
with PvuII and cloned into the StuI site of pRYGW2. Used to construct MS11 4/3/1 lgtG 
locked ON. 
plgtG+ Contains lgtG locked ON (C11 CCCCTCCGCCA); lgtG+ was amplified from Ng F62 
𝝙lgtA lgtG+ (194) with primers lal6 and lal7 and cloned into in to pCR2.1 TOPO 
(Invitrogen). Used to create lgtG locked ON. 
lgtA constructs 
plgtA Contains wildtype MS11 4/3/1 lgtA amplified with lgtA Fwd-Ext and lgtA Rev-Ext and 
cloned into pCR2.1 TOPO (Life Technologies, USA). Used as a template to construct 
lgtA locked on by site directed mutagenesis with primers lgtA-ON FWD and lgtA-ON 
REV. 
plgtA-ES Contains lgtA with ErmR-SmS from pFLOB4300 inserted into an engineered SmaI site in 
the homopolymeric tract. Used to construct unmarked lgtA mutations (ON and OFF). 
plgtA-ON Contains lgtA with homopolymeric tract locked ON (G12  GGGCGGAGGTGG) by 
SDM (Quick change Lightening Multi SDM kit; Agilent Tech) with primers lgtA-ON FWD 
and lgtA-ON REV. Used to generate lgtA locked ON. 
plgtA-del Contains WT lgtA with 417 bp deletion corresponding to bp 50-467 of the coding 
sequence. The deletion was created by double digesting plgtA with BbsI and SspI and 
ligating the larger fragment. Used to generate lgtA locked OFF (deletion). 
lgtC constructs 
plgtC Contains wildtype MS11 4/3/1 lgtC amplified with lgtC Fwd-Ext and lgtC Rev-Ext and 
cloned into pCR2.1 TOPO (Life Technologies, USA). 
Used to construct plgtC-ON and plgtC-OFF. 
plgtC-ES Contains lgtC with ErmR-SmS from pFLOB4300 inserted into an engineered SmaI site 
in the homopolymeric tract. Used to construct unmarked lgtC mutations (ON and OFF). 
plgtC-ON Contains lgtC with homopolymeric tract locked ON (G14  GGGGCGGAGG) (by SDM 
[Quick change Lightening Multi SDM kit; Agilent Tech] with primers lgtC-ON FWD and 
lgtC-ON REV. Used to generate lgtC locked ON. 
plgtC-OFF Contains lgtC with homopolymeric tract locked OFF (G14  GGTGAGGGGGGGGG) by 
SDM (Quick change Lightening Multi SDM kit; Agilent Tech) with primers lgtC-OFF 
FWD and lgtC-OFF REV. Used to generate lgtC locked OFF. 
lgtD constructs 
plgtD Contains wildtype MS11 4/3/1 lgtD amplified with lgtD Fwd-Ext and lgtD Rev-Ext and 
cloned into pCR2.1 TOPO (Life Technologies, USA). Used to construct plgtD-del and 
plgtD-ON. 
plgtD-ES Contains lgtD with ErmR-SmS from pFLOB4300 inserted into an engineered SmaI site 
in the homopolymeric tract. Used to construct unmarked lgtD mutations (ON and OFF). 
plgtD-ON Contains lgtD with homopolymeric tract locked ON (G13  GGGCGGAGGTG) by SDM 
(Quick change Lightening Multi SDM kit; Agilent Tech) with primers lgtD-ON FWD and 
lgtD-ON REV. 
Used to generate lgtD locked ON. 
plgtD-del Contains lgtD with 744 bp deletion corresponding to bp 64-808 of the coding sequence. 
The deletion was created by digesting plgtD with PflMI and NdeI and ligating the larger 
fragment. Used to generate lgtD locked OFF (deletion). 
All plasmids other than pFLOB4270 were constructed during this study.  
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Supplemental Table S3: Negative ion MS data and proposed compositions of O-
deacylated LPS from N. gonorrhoeae strains. (Average mass units were used for calculation of 
molecular weight based on proposed composition as follows: Hex, 162.15; Hep, 192.17; HexNAc, 203.19; 
PEtn, 123.05; Kdo, 220.18; Lipid A-OH, 952.00. 1The relative intensity is expressed as relative to the most 
populous glycoform/phosphoform.) 
Strain Observed 
Ions (m/z) 
(M-3H)3- 
Observed 
Ions (m/z) 
(M-2H)2- 
Molecular Mass (Da) Rel. 
Int.1 
Proposed Composition 
Observed Calculated 
5-Hex/G+ 997.2 1497.6 2995.9 2993.8 1.0 5Hex, 2HexNAc, 2Hep, 2Kdo, 
Lipid A-OH 
 
1065.0 - 3198.0 3197.0 0.4 5Hex, 3HexNAc, 2Hep, 2Kdo, 
Lipid A-OH 
5-Hex/G- 888.9 1333.8 2669.7 2669.6 0.1 3Hex, 2HexNAc, 2Hep, 2Kdo, 
Lipid A-OH 
 
930.0 1395.3 2792.8 2792.6 1.0 3Hex, 2HexNAc, 2Hep, 2Kdo, 
PEtn, Lipid A-OH 
 
970.8 - 2915.4 2915.6 0.3 3Hex, 2HexNAc, 2Hep, 2Kdo, 
2PEtn, Lipid A-OH 
 997.8 1496.7 2995.9 2995.7 0.7 3Hex, 3HexNAc, 2Hep, 2Kdo, 
PEtn, Lipid A-OH 
 1039.2 1558.5 3119.8 3118.8 0.2 3Hex, 3HexNAc, 2Hep, 2Kdo, 
2PEtn, Lipid A-OH 
4-Hex/G+ 997.2 1495.8 2994.1 2993.8 1.0 5Hex, 2HexNAc, 2Hep, 2Kdo, 
Lipid A-OH 
4-Hex/G- 888.9 1333.8 2669.7 2669.6 0.1 3Hex, 2HexNAc, 2Hep, 2Kdo, 
Lipid A-OH 
 
 
930.0 1395.3 2792.8 2792.6 1.0 3Hex, 2HexNAc, 2Hep, 2Kdo, 
PEtn, Lipid A-OH 
3-Hex/G+ 875.5 1313.5 2629.3 2630.5 0.4 4Hex, HexNAc, 2Hep, 2Kdo, 
Lipid A-OH 
 930.0 1394.7 2792.2 2792.6 1.0 5Hex, HexNAc, 2Hep, 2Kdo, 
Lipid A-OH 
 983.7 1475.7 2953.8 2954.8 1.0 6Hex, HexNAc, 2Hep, 2Kdo, 
Lipid A-OH 
 - 1496.5 2995.0 2995.8 0.2 5Hex, 2HexNAc, 2Hep, 2Kdo, 
Lipid A-OH 
 1051.5 - 3157.5 3157.9 0.1 6Hex, 2HexNAc, 2Hep, 2Kdo, 
Lipid A-OH 
3-Hex/G- - 1233.6 2469.2 2468.3 0.5 3Hex, HexNAc, 2Hep, 2Kdo, 
Lipid A-OH 
 
 
864.3 1295.4 2594.4 2591.3 1.0 3Hex, HexNAc, 2Hep, 2Kdo, 
PEtn, Lipid A-OH 
2-Hex/G+ 874.8 1313.4 2628.1 2630.4 1.0 4Hex, HexNAc, 2Hep, 2Kdo, 
Lipid A-OH 
2-Hex/G- 808.4 1212.8 2427.9 2429.1 1.0 2Hex, HexNAc, 2Hep, 2Kdo, 
PEtn, Lipid A-OH 
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Supplemental Figure S1. C4BP binding to the MS11 lgtG ‘ON’ (G+) mutants. 
Bacteria were incubated with heat inactivated human complement for 30 min at 
37 °C and bound C4BP was detected with anti-human C4BP mAb 67, followed 
by the biotinylated goat anti-mouse IgG (Molecular Probes), followed by 
Neuravidin conjugated DyLight 633 (ThermoFisher Scientific). Fluorescence was 
measured using a BD LSRII. Representative histograms from one of five 
separate experiments are shown. The number alongside each histogram 
indicates the median fluorescence intensity of the entire bacterial population.  
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CHAPTER III 
A complement enhancing chimeric antibody confers protection 
against a hypervirulent strain of Neisseria gonorrhoeae and 
circumvents antigenic variation 
 
 
 
 
 
 
 
 
Chimeric mAb(s) used in experiments described in this chapter were graciously 
provided by Genmab B/V, The Netherlands. Drs. Sunita Gulati and Bo Zheng 
assisted with the animal experiments.  
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Abstract 
Ng, the etiologic agent of gonorrhea has become resistant to multiple antibiotics. 
Experts have predicted epidemics of untreatable gonorrhea by 2020 unless 
newer therapeutics are developed. Furthermore, due to lack of broadly 
conserved immunodominant epitopes and antigenic variation, vaccine 
development has been a challenge. I have previously published the in vitro 
efficacy of murine mAb 2C7 which targets a LOS epitope seen in over 94% of 
clinically circulating Ng, despite Ng LOS glycans being highly phase variable. 
Thus, this antibody is being developed as a chimeric (2C7-Ximab; murine Fv with 
human IgG1 CH1, CH2, CH3, and CL domains) immuno-therapeutic/prophylactic. 
The susceptibility of persons with complement (C’) deficiencies to recurrent 
disseminated Ng infections suggests a role for C’ in host defenses against Ng. 
Thus, a 2C7-Ximab variant whose Fc was mutated to enhance Fc 
hexamerization (E-to-G at position 430) and C1q engagement was evaluated. I 
observed similar binding patterns of 2C7-Ximab(s) to the four distinct Ng LOS 
structures as with murine mAb 2C7 (2-Hex/G+ ≫ 4-Hex/G+ ≈ 5-Hex/G+ ≫ 3-
Hex/G+). A ~10-fold lower concentration of 2C7-Ximab with the complement-
enhancing Fc mutant was required to achieve similar killing as with wild-type Fc 
in serum bactericidal assays. While three of four Ng LOS mutants (2-Hex/G+, 4-
Hex/G+, and 5-Hex/G+) were killed by C’-mediated bacteriolysis, the fourth 
mutant (3-Hex/G+) that was serum resistant was nevertheless killed (≈ 30% 
survival) by 2C7-Ximab E430G Fc in the presence of PMNs, 2C7-Ximab E430G 
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Fc, and C’. In vivo, 2C7-Ximab E430G Fc significantly shortened the duration of 
infection caused by WT Ng, 5-Hex/G+, and 4-Hex/G+. Infections with 2-Hex/G+ 
and 3-Hex/G+ were significantly attenuated (and the Ab did not further decrease 
infection). These data confirm previous observations in human male volunteers 
that longer LOS structures (4-Hex/G+ and 5-Hex/G+) are required for durable 
infection. Thus, 2C7-Ximab represents a promising 
immunotherapeutic/prophylactic option against multidrug-resistant Ng isolates.  
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Introduction 
Gonorrhea is the second most common bacterial sexually transmitted infection 
with 78.3 million new incidences each year (3). Neisseria gonorrhoeae (Ng or the 
gonococcus), the etiologic agent of gonorrhea has become resistant to multiple 
conventional antibiotics including third generation cephalosporins, macrolides, 
and tetracyclines (39). Withdrawal of an antibiotic from therapeutic regimens 
usually does not result in reversal to susceptibility (64). Furthermore, there are no 
safe and effective vaccines licensed against Ng, necessitating an urgent need for 
novel therapeutics. 
Conventional antibiotics target metabolic processes which makes them 
amenable to bacterial subversion strategies. Antibodies (Ab[s]) physically bind to 
surface structures or secreted antigens. They either kill bacteria by recruiting 
host defenses (i.e. complement [C’], phagocytes, cytolytic NK cells) or render 
them non-infectious by disrupting critical steps in pathogenesis (neutralization). A 
murine monoclonal antibody (mAb) 2C7 (2C7-murine) reacts with 94% of clinical 
isolates of Ng (87) and shortens the duration and reduces the burden of infection 
in mice (70). 2C7-murine targets a conserved epitope (Fig. 1) within the 
gonococcal lipooligosaccharide (LOS) that is critical for pathogenesis (70). 
Therefore, resistance to mAb 2C7 because of loss of expression of the 2C7 
epitope as a result of lgtG being phase varied OFF, if it were to occur, would 
result in considerable loss of bacterial fitness. Thus, mAb 2C7 is being 
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considered as a therapeutic option against multidrug-resistant Ng. As an initial 
step, we are evaluating a chimeric IgG1 antibody with 2C7-murine Fv (2C7-
Ximab) as a therapeutic against Ng. The primary objective of this chapter was to 
demonstrate the in vivo and in vitro efficacy of 2C7-Ximab against Ng. 
Binding of 2C7-Ximab to the gonococcal LOS requires a lactose extension from 
each of the two core heptoses (Hep) I and II (Fig. 1) (139). While the expression 
of the HepI lactose is constitutive, the extension of the HepII lactose is under the 
control of the phase-variable (pv) lipooligosaccharide glycosyl transferase G 
gene (lgtG). Deleting lgtG reduces fitness of Ng in female mice (70). Three other 
pv genes, lgtA, lgtC, and lgtD contribute to variation of the HepI glycans in the Ng 
LOS (Fig. 1) (195). Of the four HepI structures that can be expressed (2-Hex, 3-
Hex, 4-Hex, and 5-Hex), the lacto-N-neotetraose (LNnT or 4-Hex) structure has 
received the most attention. The terminal galactose in strains expressing 4-Hex 
from HepI can be sialylated by α(2,3) sialyltransferase that renders Ng resistant 
to killing by complement, at least in part because of enhanced factor H binding 
(82). Moreover, (unsialylated) LNnT is also thought to play a role in transmission 
by engaging the asialoglycoprotein receptors (ASGP-R) on spermatozoa (196) 
and male urethral epithelial cells (32). However, relatively little is known about 
the role of the other HepI glycans in pathogenesis. Hence, one of the goals of 
this study was to elucidate how HepI LOS glycans affect colonization in vivo in 
the mouse infection model. As discussed in Chapter II, HepI LOS glycan 
variations modulate the in vitro binding and efficacy of 2C7-murine (122) and all 
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studies of in vivo efficacy of 2C7-murine thus far have been with a wild type 
relatively avirulent strain of Ng (126) predominantly expressing the LNnT/4-Hex 
LOS structure from its HepI (70). Consequently, a second objective was to test in 
vivo the efficacy of the 2C7-Ximab that is being considered as a therapeutic 
against the four 2C7-reactive HepI LOS glycan mutants (122) in the more 
infectious (in humans) MS11 background (126). 
The Ab initiated classical complement cascade is required for in vitro C’- 
dependent bacteriolysis of Ng; the alternative pathway alone is insufficient. C’ 
deficiencies, especially in C6, C7, and C8 were reported in patients with multiple 
episodes of disseminated gonococcal infections (77, 78) suggesting the 
importance of C’-mediated host defenses against N. gonorrhoeae. The Fc 
regions of Ab(s) that engage the globular heads of C1q form Fc hexamers when 
Ab(s) bind to surfaces. Recent advances in Ab engineering have enabled 
selective upregulation or downregulation of effector functions. Therefore, in 
collaboration with colleagues at Genmab I asked whether enhancing the C’ 
activating properties of 2C7-Ximab by Fc engineering enhanced its activity in 
vitro as well as in vivo. The glutamate (E) at position 430 in the CH3 domain of 
IgG1 forms a salt bridge with lysine (K) at position 338 in the CH2 domain, 
thereby limiting the flexibility of the CH2 — CH3 domains. A E430G mutation 
abrogates the salt bridge, and allows juxtaposed CH2 domains to adopt 
conformations more amenable to hexamer formation (197). The affinity of an 
individual Fc CH2 domain for a single globular head of C1q is very low and in the 
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order of 10-4 M (92), but multimerization enhances the avidity of the C1q – Fc 
interaction (Fig. 2). Alanine scanning mutagenesis has revealed the importance 
of D270, K322, P329, and P331 residues in Fc in C1q binding (198) (Fig. 2). 
Therefore, a 2C7-Ximab Null (D270A·K322A) Fc was used as a negative control 
to elucidate the role of C’-mediated defenses against Ng (Fig. 2).  
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Figure 1. Schematic representation of the phase-variable (pv) Ng LOS. Ng can 
express up to eight distinct LOS structures. Variation in the Ng LOS is due to pv 
of four lipooligosaccharide glycosyltransferase (lgt) genes (indicated within black 
boxes); lgtA, lgtC, lgtD, and lgtG. These genes encode enzymes that catalyze 
addition of Hex(s) to the Hep(s). Two other lgt genes, lgtF and lgtE are 
expressed constitutively and the corresponding enzymes add a lactose moiety to 
HepI. Thus, this is the LOS structure that Ng would express when all four pv 
genes are ‘OFF’. Practically, the expression of lgtG (G+) is ‘virtually’ constitutive 
(in >94% clinical samples), and this results in the addition of a lactose moiety to 
HepII. The HepI and HepII lactoses together make up the mAb 2C7 epitope 
(shaded in gray). Depending on the combinations in which lgtA, lgtC, or lgtD are 
‘ON’ or ‘OFF’, two (2-), three (3-), four (4-), or five (5-) Hex(s) may be extended 
from HepI.  
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Figure 2. Schematic representation of the three chimeric mAb 2C7(s) (2C7-
Ximab[s]). Three 2C7-Ximab(s): E430G Fc, WT Fc, and Null Fc were made by 
grafting the 2C7-murine Fv (comprising VH and VL) region on to a human IgG1 
backbone comprising the light and heavy chain constant domains. In the E430G 
Fc, the glutamate (E) at position was mutated to a glycine (G). E430 forms in the 
CH3 domain forms a salt bridge with the lysine, K338 in the CH2 domain thereby 
limiting the flexibility of the CH2 – CH3 domains. Replacing E with G, a non-polar 
amino acid abrogates this salt bridge, thereby allowing neighboring CH2 domains 
to adopt conformations more amenable to hexamer formation. The globular 
heads of the hexameric C1q engage Fc regions of Ab(s). Normally, this is a low 
affinity interaction. Multiple C1q heads simultaneously engaging Fc regions on 
multiple Ab(s) makes the interaction high avidity and results in stronger 
complement activation. The WT Fc has the native IgG1 Fc sequence, whereas in 
the Null Fc the aspartate (D) at 270 as well as the K at 322 have been both 
mutated to alanine (A). D270 interacts with R129 and K322 interacts with D162 in 
interactions with the C1q globular head (β-chain) and thus mutating these 
residues abrogate C1q binding.  
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Materials and Methods 
Bacterial strains and culture conditions 
Gonococcal strain MS11 4/3/1, a variant of MS11 VD300 and its isogenic 
mutants, 2-Hex/G+, 3-Hex/G+, 4-Hex/G+, and 5-Hex/G+ have been described 
previously (122). The lgtG was locked ‘‘ON’ in MS11 4/3/1 to generate WT-HepI 
(WT/G+) as described previously (122). Briefly, WT lgtG in the streptomycin 
resistant MS11 4/3/1 was replaced with lgtG: ErmC rpsLF62 which resulted in 
transformants that were streptomycin sensitive, but erythromycin resistant. A 
subsequent transformation in this clone with a plasmid containing the lgtG-‘ON’ 
sequence (122) resulted in homologous recombination and replacement of ErmC 
rpsLF62 with lgtG-ON; similar to the wild-type strains, this mutant was also 
streptomycin resistant and erythromycin sensitive (122). 
Ng from freezer stocks were streaked on chocolate agar (CA) plates with 
supplemented Isovitalex and incubated overnight (~18 h). For in vivo 
experiments, Ng were cultured on CA supplemented with vancomycin (V), 
colistin (C), nystatin (N), trimethoprim sulfate (TS), and Isovitalex (CA-VCNTS 
agar). Bacteria harvested from overnight cultures were sub-cultured onto fresh 
CA plates for 6 h at 37 °C in the presence of 5% CO2 for in vivo experiments. For 
in vitro assays, overnight cultures on CA plates were suspended in liquid media 
comprising Morse A and Morse B and Isovitalex for 4 hours at 37 °C with shaking 
at 250 rpm. 
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Construction, expression and purification of chimeric mAb 2C7 Ab(s) 
Three 2C7-Ximab(s) were generated by Genmab BV, The Netherlands. A 
schematic of the mAb(s) is provided in Fig. 2. The mAb(s) were produced in 
Chinese Hamster Ovary cells using Genmab’s proprietary methods. 
Human complement 
Human C’ was prepared as described previously (122). Briefly, normal human 
serum that contained NaCl 1M and 10 mM EDTA was depleted of endogenous 
IgG and IgM by passage over protein A/G (Pierce, USA) and anti-human IgM 
(Sigma) columns, respectively. Subsequently, the eluates were spin 
concentrated, equilibrated against PBS/0.1 mM EDTA and filter sterilized. All 
steps were carried out at 4 °C. Aliquots were stored at -80 °C, and thawed before 
use. 
2C7-Ximab binding assays 
The four HepI LOS mutants (107 CFU each) were incubated with 10, 31, or 100 
µg/mL of each of the three 2C7-Ximab(s) for 30 min at room temperature with 
shaking at 150 rpm. Bound Ximab was detected with FITC conjugated anti-
human IgG (Sigma) for 15 min. Fluorescence was measured by flow cytometry 
(FCM) using a LSRII (BD Biosciences, Franklin Lakes, NJ). FCM data were 
analyzed using FlowJo (v 10.2, Tree Star, Ashland, OR). 
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Serum bactericidal assays 
Serum bactericidal assays were performed as described previously (122). About 
2000 CFU of bacteria were incubated at 37 °C (with 5% CO2) in the presence of 
C’ and/or Ab(s). Aliquots were plated at 0 and 30 min and percent survival was 
calculated by expressing the number of CFU at 30 min as a percent of the 
number of CFU at 0 min. C1q depleted sera and purified C1q were purchased 
from Complement Technology, Inc., USA. 
PMN killing and association assays 
PMN killing assays were performed as previously described (122). Briefly, PMNs 
were isolated from freshly drawn venous blood over a Percoll gradient (density 
1.130 g/mL; GE Lifesciences) after initial separation over Histopaque K119 
(Sigma). PMNs were then adhered on to tissue culture coated plastic cover slips 
(Sarstedt, Germany) following which they were infected with either opsonized or 
un-opsonized Ng at a MOI of 1. Aliquots were plated at 0 and 60 min and percent 
survival was calculated by expressing the number of CFU at 60 min as a percent 
of the number of CFU at 0 min. For association assays, adherent PMNs were 
infected with Hoechst 33342 labeled bacteria at a MOI of 10. Adherent PMNs 
were scraped off after an hour, washed and analyzed by FCM over a BD LSRII. 
Un-opsonized bacteria and non-infected PMNs were used as controls. 
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Complement C1q binding and C3 deposition assays 
Approximately 107 CFU of Ng were incubated (in the presence of absence of 
2C7-Ximab[s]) either with 20% C’ (for C3 deposition) or with 3 µg of C1q (for C1q 
binding) for 15 min. C3 deposited on bacteria was stained with FITC conjugated 
sheep anti-human C3c (Bio-Rad) for 15 min. Paraformaldehyde (2%) was added 
to reactions and incubated for 10 min at 37 °C. C1q associated with bacteria was 
detected with biotinylated anti-C1q (JL-1 clone, Abcam) for 30 min, followed by 
streptavidin – DyLight633 (Thermo Fischer) for 15 min. 
In vivo infection studies 
Six to eight weeks old female BALB/c mice (Jackson Laboratories) were infected 
with Ng as described previously (70). Briefly, mice were selected in the diestrus 
phase of estrous cycle and administered 0.1 mg Premarin (Pfizer) per day 
subcutaneously as a single dose on days -2, 0, and +2. Mice were also given two 
daily intra-peritoneal doses of 0.6 mg of vancomycin (Mylan pharmaceuticals) 
and 0.3 mg of streptomycin (X-gen pharmaceuticals) on days -2, -1, and 0. 
Premarin, streptomycin, and vancomycin were all diluted in sterile water. On day 
0, mice were infected intra-vaginally with 106 CFU of one of the five Ng mutants: 
WT/G+, 5-Hex/G+, 4-Hex/G+, 3-Hex/G+, or 2-Hex/G+. Animals in the treated 
groups received 1 or 0.1 µg of 2C7-Ximab E430G Fc in saline intra-vaginally 
daily beginning on day 0. Control groups were administered saline. Vaginal 
swabs were collected daily for 9 days; bacteria in swabs were eluted in 100 µL 
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saline. Bacterial burdens were monitored by quantitative cultures of vaginal swab 
eluates on CA-VCNTS agar. Mice were declared to have cleared the infection 
after three successive negative cultures. 
Statistical analyses 
One-way ANOVA was employed to compare multiple groups using Tukey’s post-
hoc test for pair-wise comparisons. Two-way ANOVA was used to compare 
groups when concentration was a variable. In vivo clearance experiments were 
tested for: time to clearance, longitudinal trends in mean log10 CFU, and the 
cumulative CFU (area under the curve [AUC]). Kaplan-Meier survival curves 
yielded the median times to clearance; Mantel-Cox log-rank test was used to 
compare times to clearance between groups. Significance was set using 
Bonferroni’s correction for number of pairwise comparisons when more than two 
groups were compared – for example, a significant P value when three groups 
were compared was set at 0.017 (0.05/number of possible pairwise comparisons, 
which is 3). Bacterial burdens were determined for each group by averaging the 
area under the curve (log10CFU vs. time) for each mouse. Bacterial burdens were 
then compared using ANOVA (Kruskal-Wallis test).  
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Results 
Point mutations in the Fc region(s) of 2C7-Ximab(s) do not alter binding to 
HepI LOS mutants; HepI LOS glycans modulate 2C7-Ximab binding 
Binding of the three 2C7-Ximab(s), WT Fc, E430G Fc, and Null Fc to the 
previously described (122) Ng HepI LOS mutants was measured by FCM using 
concentrations of 10, 31, and 100 µg/mL. Each HepI mutant bound similar 
amounts of all three 2C7-Ximab(s) (Fig. 3). However, the amount of antibody 
binding varied across the four HepI mutants. Maximum 2C7-Ximab binding was 
observed with the 2-Hex/G+ mutant followed by the 4- and the 5-Hex/G+, while 
the 3-Hex/G+ bound the least (Fig. 3). These binding patterns were consistent 
with those observed previously with 2C7-murine (122). At concentrations below 
10 μg/mL, the 2-Hex/G+ was the only mutant that showed binding above control 
values (dotted lines in Fig. 3); binding to the other mutants above control values 
was not discernable (data not shown).  
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Figure 3. All three 2C7-Ximab(s): E430G Fc, WT Fc, and Null Fc show similar 
amounts of binding to all four HepI LOS mutants containing the 2C7-epitope. 
Among the four mutants, maximum binding was observed to the 2-Hex/G+ 
mutant, followed by the 4-Hex/G+ and 5-Hex/G+ mutants. The 3-Hex/G+ mutant 
shows the least amount of 2C7-Ximab binding. The dashed line in each graph 
represents the fluorescence levels of the conjugate control. Each data point 
represents the mean fluorescence observed in 3 replicate experiments (±SEM).  
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A E430G mutation in the Fc region of 2C7-Ximab enhances serum 
bactericidal efficacy against Ng 
The E430G mutation was originally described for anti-CD38 or anti-CD20 Ab(s) 
targeting cells of the B-cell lineage (198) with diameters ranging from 5 to >12 
µm. In comparison, the average diameter of Ng is about 1 µm and 2C7-Ximab 
targets an epitope within the most abundant molecule on the Gram-negative 
outer membrane, the LOS. Hence, we speculated that the spatial distribution of 
WT Fc may already favor optimal C’ activation, and E430G Fc may confer no 
added benefit. To test this hypothesis, we performed serum bactericidal assays 
on the 2-Hex/G+ mutant with 20% human C’ (IgG and IgM depleted normal 
human serum) and 10, 31, 100, or 316 µg/mL of E430G Fc and WT Fc. The 2-
Hex/G+ mutant was chosen because this mutant bound the maximum amounts 
of 2C7-Ximab. Survival was represented by comparing the number of CFU at 30 
mins compared to the number of CFU at 0 mins. Contrary to my expectations, 
the E430G Fc showed significantly more bactericidal activity than the WT Fc at 
31 and 100 µg/mL, thereby showing a positive impact of Ab hexamerization on C’ 
activation and Ng killing (Fig. 4a). As expected, the Null Fc which is engineered 
to abrogate C1q-Fc interactions did not cause any C’ dependent bacteriolysis 
(survival >100%) even at 316 µg/mL (Fig. 4b).  
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Figure 4. Serum susceptibility of the 2-Hex/G+ mutant in the presence of 2C7-
Ximab(s). (a) 2C7-Ximab E430G Fc is bactericidal for the 2-Hex/G+ mutant at a 
log10-fold lesser concentration compared to WT Fc. Each bar represents the 
mean of 2 replicates (±range). Groups were compared using 2-way ANOVA (*, P 
= 0.0133; ****, P = <0.0001). (b) The Null Fc does not have any cidal activity. 
Survival was calculated by expressing the number of colonies at T=30 min as a 
percent of the number of colonies at 0 min.  
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The enhanced bactericidal activity of 2C7-Ximab E430G Fc is associated 
with increased C1q binding 
To confirm that the increased bactericidal activity of the E430G Fc was indeed 
due to the C1q recruitment enhancing property of the E430G mutation (92, 197), 
I measured C1q deposition on the 2-Hex/G+ mutant in the presence of 31, 56, or 
100 µg/mL of each of the three 2C7-Ximab(s) by FCM. In every instance, I 
observed significantly more C1q recruitment by the E430G Fc compared to the 
WT Fc. The WT Fc recruited more C1q than the Null Fc (significant at 56 and 
100 µg/ml). Minimal C1q recruitment was noted in the absence of 2C7-Ximab 
(Fig. 5a and Suppl. Fig. 1). No killing of Ng was observed when E430G 
opsonized bacteria were incubated with C1q depleted serum; the addition of 
purified C1q reconstituted the bactericidal activity of serum (Fig. 5b). Collectively, 
these observations suggest that the enhanced bactericidal activity of E430G Fc 
is directly linked to its ability to increase C1q recruitment and classical C’ 
pathway activation.  
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Figure 5. Enhanced C1q recruitment is necessary for the enhanced bactericidal 
efficacy of 2C7-Ximab E430G Fc. (a) E430G Fc binds significantly more C1q 
than WT Fc on the 2-Hex/G+ mutant at each tested concentration. Each bar 
represents the mean of 2 replicates (±range). Comparisons across groups was 
made using 2-way ANOVA (*, P < 0.05; **, P = <0.01; ***, P < 0.001). (b) C1q is 
necessary for bactericidal activity of E430G. Serum bactericidal assays with the 
2-Hex/G+ mutant was performed with 20% C1q depleted NHS (ΔC1q NHS) or 
ΔC1q NHS reconstituted with pure C1q (70 μg/ml). Each bar represents the 
mean of 2 replicates (±range). Comparison between groups were made using 
one-way ANOVA. Overall P value was 0.0112 (*, P < 0.05).  
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The ability of 2C7-Ximab E430G Fc to activate the classical C’ cascade is 
regulated by Ng HepI LOS glycans 
Next, I tested the bactericidal activity of E430G Fc against the three other HepI 
LOS mutants. Serum bactericidal assays were performed with 20% C’ and 31, 
100, or 178 µg/mL of E430G Fc. As shown in Fig. 4a, only the 2-Hex/G+ mutant 
was sensitive to the bactericidal effects of E430G Fc at 31 µg/mL, while the 4-
Hex/G+ and the 5-Hex/G+ mutants were killed (<50% survival) in the presence of 
100 µg/mL and 178 µg/mL of E430G Fc respectively (Fig. 6). The 3-Hex/G+ 
mutants remained fully serum resistant (>100% survival) at 178 µg/mL; further 
increasing mAb concentrations to 500 µg/mL caused no killing (data not shown). 
Thus, the serum bactericidal assays were consistent with 2C7-Ximab binding 
patterns. Sensitivity to C’ in presence of 2C7-Ximab mimicked observations with 
2C7-murine (122).  
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Figure 6. Bactericidal efficacy of 2C7-Ximab E430G Fc follows binding patterns. 
Serum bactericidal assays were done with 20% human C’ as described 
previously. Each bar represents the mean of 2 replicates (±range).  
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3-Hex/G+ is killed by PMNs in a complement dependent manner upon 
opsonization with 2C7-Ximab(s) 
Our previous studies demonstrate that even though the 3-Hex/G+ mutant was 
resistant to direct C’-mediated bacteriolysis, C’ activation mediated by 2C7-
murine opsonization was sufficient to facilitate killing by PMNs (122). Therefore, 
to assess if 2C7-Ximab(s) also could activate the classical cascade on 3-Hex/G+, 
we measured C3 deposition by FCM. Both E430G Fc and WT Fc deposited C3 
on the 3-Hex/G+ mutant. Although not statistically significant, there was a trend 
toward higher C3 deposition by the E430G Fc at both 100 and 200 µg/mL 
compared to the WT Fc (Fig. 7a). Next, I investigated whether opsonization with 
2C7-Ximab, either alone or in conjunction with C’ results in killing of the 3-
Hex/G+ mutant by freshly isolated human PMNs. To assess the effects mediated 
only by Ab and C’, the 3-Hex/G+ mutant was made in MS11 where all 11 Opa 
proteins were deleted (MS11 ΔOpa; kindly provided by Dr. Daniel C. Stein, 
University of Maryland; (168)) as CEACAM3 on PMNs can bind to Opa(s) and 
mediate non-opsonic phagocytic killing. Survival was calculated by expressing 
the number of CFU at 60 min as a percent of the number of CFU at 0 min. PMNs 
failed to kill bacteria opsonized with either of the 2C7-Ximab(s) alone at 100 
µg/mL. However, a significant decrease in survival was observed when bacteria 
were incubated with PMNs in the presence of E430G Fc and C’. In contrast, the 
WT Fc plus complement did not significantly reduce survival (Fig. 7b).  
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Figure 7. 2C7-Ximab E430G Fc deposits more C3 on the 3-Hex/G+ mutant 
compared to WT Fc and mediates killing by PMNs. (a) C3 deposition on the 3-
Hex/G+ mutant. Control reactions included bacteria incubated with 20% C′ alone 
and are shown by the dashed line. The geometric mean of the fluorescence is 
represented (mean of 2 replicates ±range). Groups were compared using 2-way 
ANOVA; differences between E430G Fc and WT Fc were not significant. (b) 
2C7-Ximab E430G Fc facilitates opsonophagocytosis of 3-Hex/G+ by PMNs in 
the presence of C’. Percent survival (CFU at 60 min relative to CFU at 0 min) is 
shown on the Y-axis. Each bar represents the mean of the percent survival of 3 
separate experiments using PMNs from a single donor (±range). A comparison of 
killing across the four groups that contained PMNs was performed by one-way 
ANOVA, using Tukey’s multiple comparison test (Overall P value = 0.0007; *, P < 
0.05, **, P < 0.01). The strain used in these assays lacked all 11 Opa proteins 
thus reducing noise from Opa – CEACAM interactions.  
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The E430G Fc mutation does not enhance association with human PMNs  
The data in Fig. 7b show that Opa-negative Ng are not killed when PMNs are 
incubated with Ng opsonized with either WT Fc or E430G Fc alone. I next asked 
if the E430G mutation affected association of Opa-negative Ng with human 
PMNs. Therefore, I assessed the association of fluorescently labelled bacteria 
with freshly isolated human PMNs in the presence or absence of 100 µg/mL of 
each of the three 2C7-Ximab(s) to look for differences in FcƔR engagement. To 
reduce background signal because of Opa-CEACAM interactions, we used a MS 
11 ΔOpa mutant with a WT LOS. Opsonization with the 2C7-Ximab(s) enhanced 
the association of bacteria with PMNs; only E430G Fc and WT Fc significantly 
enhanced association of bacteria with PMNs over baseline levels (no added 
mAb) levels. I speculate that the increased association compared to non-
opsonized bacteria is because of FcƔR engagement (Fig. 8a). Although 
association of Ng with PMNs was higher with the E430G Fc and WT Fc when 
compared to association seen with the Null Fc, these differences were not 
statistically significant. As shown in Fig. 7b, enhanced association of bacteria 
with PMNs did not translate to enhanced killing at 60 min as there were no 
differences in survival between non-opsonized bacteria and Ng opsonized with 
100 µg/mL 2C7-Ximab in the presence of PMNs (Fig. 8b). Note that the presence 
of PMNs alone (no added Ab) resulted in a decrease in survival compared to 
bacteria in media alone (no PMNs or Ab).  
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Figure 8. Opsonization of MS11 ΔOpa with 2C7-Ximab increases association 
with, but not killing by PMNs. (a) Opsonization with 2C7-Ximab(s) results in 
enhanced association of Ng with PMNs. Adherent PMNs were infected with 
Hoechst 33342 labeled bacteria at a MOI of 10. Fluorescently labeled bacteria 
were opsonized with 100 μg/mL of each of the three 2C7-Ximab(s). Un-
opsonized bacteria and non-infected PMNs were used as controls. Groups were 
compared using one-way ANOVA (**, P < 0.01; ***, P < 0.001). (b) Enhanced 
association of 2C7-Ximab opsonized bacteria does not result in enhanced killing 
by PMNs. In killing assays, no difference in survival was noted between 
opsonized or un-opsonized bacteria exposed to PMNs. Groups were compared 
by ordinary one-way ANOVA (*, P = 0.05).  
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All HepI LOS mutants colonize mice, but longer HepI glycans are required 
for prolonged infection 
HepI glycan structures affect pathogenesis and virulence in the human male 
volunteer infection model of gonorrhea (125, 199). I aimed to evaluate the effects 
of HepI glycan extensions on the virulence of Ng in the mouse vaginal 
colonization model using the four mutants with lgtG locked ON (G+). Only the G+ 
mutants were chosen because loss of lgtG expression significantly attenuates 
infection in mice (70, 89). I included a mutant that had only lgtG locked on 
(WT/G+), which unlike the other four mutants, permitted HepI phase variation. 
This mutant would also provide information about a role for HepI phase variation, 
if any, in pathogenesis. 
Mice were infected with 106 CFU of Ng intra-vaginally. Vaginas were swabbed 
and cultured daily to monitor the burden of infection. The 4-Hex/G+ and WT/G+ 
were the most infective and both these mutants caused similar durations (median 
time to clearance was 7 d; Fig. 9a) of infection, CFU over time (Fig. 9b) and 
overall burdens of infection (as measured by AUC; Fig 9c). The 5-Hex/G+ which 
in addition also expresses the sialylatable LNnT epitope (122) showed 
intermediate infectivity (median time to clearance 5.5 days). The 2- and the 3-
Hex/G+ mutants infected mice only transiently (median times to clearance 3 
days; Fig. 9a) and had a significantly lower overall burden of infection (Fig. 9c). 
Times to clearance of infection were compared (two groups at a time) using the 
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Mantel-Cox log-rank test and results are indicated in Table 1. Significance was 
set at 0.005 (Bonferroni’s correction for 10 possible pairwise comparisons). Our 
results show that while shorter HepI glycans (i.e., 2- and 3-Hex/G+) can colonize 
mice, the infection is transient with low overall bacterial burdens (Fig. 9). Longer 
and more robust infection is favored by longer HepI glycans, possibly because of 
expression of the sialylatable LNnT LOS, which is consistent with prior 
observations in mice and men (125, 199).  
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Figure 9. Longer 
HepI glycans are 
required for 
prolonged and 
robust infections in 
vivo. (a) Mutants 
with 4 or 5 Hex(s) 
extending from 
HepI cause 
prolonged 
infections in mice. 
WT/G+ has a 
predominantly 4-
Hex/G+ phenotype 
(data not shown). 
Median times to 
clearance for the 
4-Hex/G+ and 
WT/G+ mutants 
were 7d. The 
median time to 
clearance was 5.5 
d for the 5-Hex/G+ 
mutant, whereas 
median times to 
clearance for the 
2-Hex/G+ and 3-
Hex/G+ mutants were 3 d. Kaplan-Maier (KM) curves were plotted to determine 
median times to clearance. Mutants were compared pairwise using the Mantel-
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Cox log rank test to determine differences in clearance times indicated in Table 
1. (b) Mutants with 4 or 5 Hex(s) extending from HepI cause infections with 
higher bacterial burdens. The number of colonies recovered from all animals 
infected with a particular mutant were averaged (±SEM) and plotted against time. 
(c) Mutants with longer HepI LOS glycans cause more robust infections compared to 
mutants with shorter HepI glycan extensions. The AUC (log10 CFU) for each mouse is 
plotted. Horizontal lines represent the geometric means of AUCs for each group. Groups 
were compared using one-way ANOVA (Kruskal-Wallis) test (**, P < 0.01; ***, P < 0.001; 
****, P < 0.0001).  
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Table 1: Comparison of median times to clearance of infection (Mantel-Cox) 
log-rank test 
 2-Hex/G+ 3-Hex/G+ 4-Hex/G+ 5-Hex/G+ 
3-Hex/G+ ns    
4-Hex/G+ 0.0002 <0.0001   
5-Hex/G+ 0.0002 0.0004 <0.0001  
WT/G+ 0.0002 <0.0001 ns <0.0001 
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E430G 2C7-Ximab shortens duration of colonization in mice infected with 
‘virulent’ mutants 
Finally, we asked if the E430G Fc (the 2C7-Ximab with superior in vitro activity) 
was effective in vivo. Ongoing work in our group has demonstrated that activation 
of C’ is indeed important for clearance of Ng infections using two approaches. 
First, 2C7-Ximab Null Fc fails to clear infections and second, 2C7-Ximab E430G 
is ineffective in C1q knockout mice (Sunita Gulati; personal communication, 
2017). Mice infected with HepI LOS mutants were administered either 1 or 0.1 µg 
E430G Fc daily, and CFU recovered from treated mice were compared to those 
from untreated mice to determine efficacy of the immunotherapeutic. Note that 
the control arm (no mAb) for this experiment is the same as shown in Fig. 9; the 
data have been shown separately for ease of interpretation. For the 2-Hex/G+ 
and 3-Hex/G+ mutants, the median times to clearance of infection in untreated 
mice (3 days) were similar to mice treated with E430G Fc (2.5 – 3 days) (Fig. 10a 
and 10b). Bacterial burdens between the treated and untreated groups were also 
similar (Suppl. Fig. 4a and 4b). Hence, therapy did not confer any added benefit 
in these attenuated mutants. For the 4-Hex/G+, 5-Hex/G+ and WT/G+, the 
median times to clearance in mice treated with 1ug/day of E430G Fc were 2 – 
2.5 days, whereas that in mice treated with 0.1ug/day they were 2.5 – 3 days 
(Fig. 11a, 11b, and 11c). The median times to clearance in untreated mice were 
7 days for the 4-Hex/G+ and the WT/G+ mutants, and 5.5 days for the 5-Hex/G+ 
mutant. For these three mutants, the bacterial burdens in the treated groups 
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were also significantly lower compared to the untreated groups (Suppl. Fig. 5a, 
5b, and 5c). The higher dose of 1ug/day of E430G Fc did not provide any added 
benefit compared to 0.1ug/day.  
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Figure 10. Treatment with 2C7-Ximab E430G does not further attenuate 
infection by the 2-Hex/G+ or 3-Hex/G+ mutants. (a) Treatment does not 
significantly shorten infection in mice infected with 2-Hex/G+ mutants. (b) 
Treatment does not significantly shorten infection in mice infected with 3-Hex/G+ 
mutants. Treated mice received 1 or 0.1 µg of 2C7-Ximab E430G Fc in saline 
intra-vaginally everyday starting on day 0. Control groups were administered 
saline. KM curves were compared as described previously.  
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Figure 11. 2C7-Ximab E430G Fc shortens infection in mice infected with 4-
Hex/G+, 5-Hex/G+, and WT/G+ mutants. Treatment of mice with 1.0 or 0.1 µg 
intra-vaginally daily significantly shortens the duration of infection with 4-Hex/G+ 
(a), 5-Hex/G+ (b) and WT/G+ (c) mutants compared to control saline treated 
animals. Significance is set at 0.017 (Bonferroni’s correction for three pairwise 
comparisons in each group).  
 
125 
Discussion 
Ng has become multidrug resistant. Strains resistant to even third generation 
cephalosporins such as ceftriaxone have been identified worldwide (37, 39, 64, 
131), and it has been suggested that by 2020 untreatable strains of gonorrhea 
could be widespread (39, 64). Prior work by our group had identified a 
monoclonal antibody (2C7-murine) that reacted with > 94% of circulating strains 
of Ng (87, 122). Therefore, this mAb has the potential to be developed as an 
immunotherapeutic (or immunoprophylactic), which led to developing the 2C7-
Ximab(s) in collaboration with colleagues at Genmab. Since C’ deficiencies have 
been associated with a predisposition to recurrent Neisserial infections (77, 78, 
90), we reasoned that the introduction of C’ enhancing properties (the E430G 
mutation) in the Fc region of 2C7-Ximab would render it more effective. This is 
especially important since Ng possesses multiple mechanisms to escape the 
bactericidal effects of C’, including binding of the C’ inhibitors, FH and C4BP 
(200, 201). 
The in vitro findings reported here support the greater potency of 2C7-Ximab 
E430G Fc over 2C7-Ximab WT Fc. Similar to our observations with 2C7-murine, 
HepI LOS glycans modulated the binding and functional efficacy of all 2C7-
Ximab(s). A comparison between the E430G Fc and WT Fc revealed that E430G 
Fc not only promotes direct C’ mediated bacteriolysis, but also C’ dependent 
PMN mediated killing at lower doses than the WT Fc (Ab opsonization alone in 
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the absence of C’ results in association of bacteria with PMNs, but does not 
cause killing). Further, in the murine vaginal colonization model, we 
demonstrated the ability of E430G Fc to clear infections by Ng mutants with two 
(4-Hex/G+ and 5-Hex/G+) of the four HepI LOS phenotypes associated with the 
relevant lgtA/C/E phase variation combinations. An important observation with 
the uninfected controls was that mutants with longer (4-Hex) HepI LOS structures 
resulted in durable infection. The 5-Hex mutant also expresses the 4-Hex 
structure, which is modified by sialic acid in vivo (177), a glycan substitution that 
is critical for establishing infection both in human male volunteers and in the 
female BALB/c mouse model. 
While the role of HepI glycans in pathogenesis has not been defined previously 
in the context of the murine vaginal colonization model, most human studies 
have used WT strains that predominantly express the 4-Hex HepI glycan 
structure. To our knowledge, only two studies have examined the role of pv of 
HepI glycans in vivo. In these studies, human male volunteers were 
experimentally challenged with a wild-type Ng variant whose HepI glycan was 
predominantly 2-Hex, with traces of 4-Hex (MS11 mkA). Recovered bacteria 
expressed 2-Hex HepI glycans transiently until the onset of dysuria. However, 
with the progression of infection, the observed HepI LOS phenotypes became 
predominantly 4-Hex and 5-Hex (also called the MS11 mkC variant) (199). In a 
separate study, the infectious dose of MS11 mkA was determined to be higher 
than MS11 mkC (125). The caveat in interpreting these experiments is that 
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although MS11 mkA predominantly expresses the 2-Hex structure from HepI, it 
expresses a small amount of the 4-Hex structure too. Therefore, the contribution 
of only the 2-Hex structure in initiation of infection could not be ascertained. 
Nevertheless, these studies provided evidence that Ng expressing short HepI 
glycans may not cause sustained infection. My studies in mice using LOS 
mutants with non-variable structures strongly suggest that longer (4- and 5-Hex) 
HepI glycans are necessary for durable infection, and confirm the findings of 
Schneider and colleagues in human male volunteers. 
The simplest model of STI dynamics states that R0 = βDc, where R0 is the 
average number of secondary cases of infection generated by a primary case in 
a susceptible population, β is the probability of transmission within a sexual 
partnership, c is the number of new sex partners the infected person has in a unit 
of time and D is the duration the person is infectious (202, 203). An R0 >1 implies 
that an infection will persist, while an R0 <1 predicts elimination of infection. Thus, 
even a modest decrease in the duration and burden of Ng infection will 
profoundly impact transmission. We therefore posit that even if the 2-Hex/G+ and 
3-Hex/G+ mutants cause attenuated infection in humans, they may not reach the 
threshold that is conducive for Ng transmission and spread within a sexual 
network. 
While the propensity of Neisserial infections in C’ deficient individuals is well 
recognized, the in vivo mechanism of action of 2C7-Ximab remains unclear. 
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Unpublished studies demonstrate that depletion of PMNs or macrophages do not 
affect the ability of 2C7-murine to clear infections (Dr. Sunita Gulati, personal 
communication), suggesting a role for C’ in clearance of infection. However, 
PMNs are important innate effector cells and human PMNs contribute to Ab and 
C’-dependent killing of Ng in vitro (22, 122, 204-210). Moreover, inherent 
differences between murine and human PMNs (discussed in Chapter IV) makes 
interpretation of the in vivo PMN depletion experiment ambiguous. Therefore it 
would be premature to dismiss the role of PMNs in clearance of Ng infections 
without further studies – for example, studies in mice that possess functional 
human neutrophils may help address this question (211). The requirement for the 
classical pathway was recently demonstrated using C1q Knock-out (KO) mice, 
which failed to clear infection despite 2C7-Ximab treatment. Moreover, due to the 
species-specific binding of C’ inhibitors by Ng (212, 213), the efficacy of 2C7-
Ximab E430G Fc was also tested in human C4BP and FH dual transgenic (Tg) 
mice. The dual Tg mice cleared infection albeit less well compared to WT BALB/c 
mice at similar doses of 2C7-Ximab E430G Fc (Dr. Sunita Gulati, personal 
communication). 
Future studies will focus developing a fully humanized mAb 2C7 E430G Fc will 
likely reduce the potential immunogenicity (anti-drug Ab). Further, my studies 
have addressed the use of 2C7-Ximab given intra-vaginally. This is relevant for 
its use as an immunoprophylactic (e.g. as delivery via vaginal rings or as topical 
gel formulations), but not as treatment for established disease. Therefore, mouse 
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studies in which 2C7-Ximab is administered systemically will be carried out to 
investigate its use for the treatment of established disease.  
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Supplementary Materials 
Supplementary Figure 1. C1q recruitment by the 2C7-Ximab(s) on the 2-
Hex/G+ mutant. Representative histograms of C1q deposition assays. Bacteria 
were harvested from overnight cultures on chocolate agar plates and sub-
cultured in liquid medium for 4 h with shaking at 37 °C at 250 rpm. Ng were 
suspended to a turbidity of 0.4. Hundred μL of bacterial suspension was washed 
and re-suspended in HBSSCa2+Mg2+ and incubated with 31, 56, or 100 μg/mL 
2C7-Ximab(s) and 3 μg of purified C1q for 10 mins with shaking at 150 rpm at 36 
°C. Subsequently the reaction mixture was fixed with paraformaldehyde at 37 °C 
with an equal volume of 2% paraformaldehyde for 10 mins. The reaction was 
washed with buffer and bound C1q was tagged using Biotinylated anti-C1q Ab 
[JL-10 clone] (Abcam). Biotinylated Ab was detected using Streptavidin-DyLight 
633 (Fisher) over a BD LSRII flow cytometer.  
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Supplementary Figure 2. 
C1q recruitment by the three 
2C7-Ximab(s) on MS11 
ΔOpa. E430G Fc recruits 
significantly more C1q 
compared to WT Fc and Null 
Fc. C1q deposition assays 
were done as described 
previously. Geometric means 
of fluorescence were 
recorded and normalized to 
C1q deposited on bacteria 
opsonized with 100 μg/mL of 
E430G Fc. Each bar 
represents the mean of 2 experiments (±range). Groups were compared using 2-
way ANOVA (*, P < 0.05; **, P < 0.01; ***, P < 0.001). MS11 ΔOpa predominantly 
expresses a 4-Hex/G+ LOS (data not shown).  
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Supplementary Figure 3. C3 
deposition by the three 2C7-
Ximab(s) on MS11 ΔOpa. 
E430G Fc recruits significantly 
more C3 compared to WT Fc 
and Null Fc. C3 deposition 
assays were done as 
described previously. 
Geometric means of 
fluorescence were recorded. 
Each bar represents the mean 
of 2 experiments (±range). 
Groups were compared using 
ordinary one-way ANOVA (*, P 
< 0.05; **, P < 0.01; ***, P < 0.001). MS11 ΔOpa predominantly expresses a 4-
Hex/G+ LOS (data not shown).  
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Supplementary Figure 4. Bacterial burdens are similar in treated and untreated 
groups of mice infected with 2-Hex/G+ (a) and 3-Hex/G+ (b) mutants. In the 
CFU/100 μL (left graphs) each data point is the mean of all animals (±SEM). In 
the AUC (right graphs) the dash indicates the geometric mean.  
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Supplementary Figure 5. E430G Fc significantly reduces the bacterial burden in 
mice infected with 4-Hex/G+ (a), 5-Hex/G+ (b), and WT/G+ (c) mutants. Mice 
were treated with 2C7-Ximab E430G at doses of 1.0 μg/d, 0.1 μg/d or with saline 
(vehicle control). The graphs on the left show mean log10 CFU vs time, while the 
graphs on the right show AUC (log10 CFU). The horizontal lines depict the 
geometric means for each group. AUCs were compared using one-way ANOVA 
(Kruskal-Wallis) test (*, P < 0.05; **, P < 0.01; ***, P < 0.001).  
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CHAPTER IV 
Discussion 
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Rationale, objectives, and salient findings of this dissertation 
Globally, there are 78.3 million new cases of gonorrhea reported each year 
(214). Mucosal inflammation associated with gonorrhea enhances the risk of 
transmission, as well as acquisition of HIV (215). Moreover, gonorrhea places a 
significant economic burden. In 2013, the estimated direct medical costs for 
treating gonorrhea in the US were 162.1 million (range: 81.1 – 243.2 million) 
USD (216). Along with its sequelae, the cost of treatment of gonorrhea is thought 
to be upwards of 10 billion dollars in the United States alone. Furthermore, 
between 2010 – 2014, a >3-fold rise urgent care center visits were recorded for 
patients seeking treatment for gonorrhea in comparison to previous years (217). 
To make matters worse, Ng, the etiologic agent of gonorrhea has acquired 
resistance to every antibiotic approved for use against it (64). There are no safe 
and effective vaccines against gonorrhea available yet. Some experts predict that 
epidemics of drug resistant gonorrhea will become commonplace by 2020 (39). 
Thus, gonorrhea is a major public health concern, and there is an urgent need for 
the development of vaccines and novel therapeutics against Ng. 
Vaccine development against gonorrhea has been limited by lack of interest from 
the pharmaceutical sector, paucity of immunodominant epitopes that elicit 
protective Ab(s), variable expression of Ag(s) and widespread Ag variation (66). 
Studies of gonococcal LOS led to the identification of mAb 2C7, a murine 
monoclonal that reacts with >94% of Ng strains (87). LOS is a ubiquitous Ag and 
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an important virulence determinant. Moreover, the epitope recognized by mAb 
2C7 has been demonstrated to be critical for pathogenesis in vivo (70, 89). 
Active immunization with a peptide mimic of the mAb 2C7 epitope (mimitope), as 
well as passive immunization with the antibody itself resulted in shortened 
duration of infection as well as lower bacterial burdens (70). Therefore, mAb 2C7 
and its mimitope are being developed as an immunotherapeutic/prophylactic and 
a vaccine candidate respectively. 
Gonococcal LOS is a highly variable structure on account of SSM of four pv 
genes (lgtA, lgtC, lgtC, and lgtG) (122). More than 94% of the clinical strains of 
Ng express the mAb 2C7-epitope, implying that the lgtG is turned ‘ON’ (87). The 
HepI phenotypes determined by the three other lgt genes appears to be more 
variable (122). Thus, mAb 2C7-reactive strains can express one or more of four 
distinct HepI LOS forms: 2-Hex/G+, 3-Hex/G+, 4-Hex/G+, 5-Hex/G+. However, 
efficacy studies with 2C7-murine have been conducted with a relatively avirulent 
WT strain (FA1090) predominantly expressing one LOS structure (4-Hex/G+) 
(70, 125, 218). 
The significance of gonococcal HepI LOS structures other than the 4-Hex 
structure in virulence remains poorly understood. Thus, one of the goals of this 
dissertation was to investigate the effects of HepI LOS structures on Ng 
infectivity in vivo. The three pv lgt genes controlling HepI LOS structures of Ng 
have been evolutionarily conserved in this ancient pathogen unique to humans. 
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Therefore, it is reasonable to hypothesize that each structure plays a role in 
infection. Hence, it was important to determine whether a mAb 2C7-based 
vaccine or immunotherapeutic would be effective against the different HepI LOS 
structural variants, and whether Ab(s) targeting the mAb 2C7 epitope would be 
functional against more virulent isolates such as MS11. Furthermore, since 
recurrent Ng infections have been associated with C’ deficiencies, we sought to 
answer if enhancing the C’ activating abilities of 2C7-Ximab confers any 
therapeutic benefit. 
To answer the questions in the preceding paragraph a well-studied isolate of Ng, 
MS11 was chosen as the background strain. With an infectious dose as low as 
250 bacteria in human male volunteers, MS11 is more virulent than FA1090 
(125). I constructed mutants in MS11 such that each mutant expressed one of 
the eight distinct LOS structures (other structures that result from LOS being 
exported to the outer membrane before all the Lgt(s) have added their substrate 
were also present). While four of these mutants (5-Hex/G-, 4-Hex/G-, 3-Hex/G-, 
and 2-Hex/G-) lacked the mAb 2C7 epitope and were used as controls, the G+ 
mutants that bound the Ab were used for the studies described in this 
dissertation because lgtG- (or variants that do not express HepII glycans) 
mutants are attenuated in mice and rarely found in nature (70, 89). 
HepI LOS glycans regulated the binding of 2C7-murine. Highest binding was 
observed to the 2-Hex/G+ mutant, followed by the 4-Hex/G+ and the 5-Hex/G+ 
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mutants. The 3-Hex/G+ mutant bound significantly lower amounts of 2C7-murine. 
Differences in Ab binding translated to differences in activation of the classical C’ 
pathway by 2C7-murine. The 2-Hex/G+ mutant was killed by 4 µg/mL of 2C7-
murine, 4-Hex/G+ and 5-Hex/G+ were killed by 10 µg/mL, while the 3-Hex/G+ 
remained resistant even at 10 µg/mL. Resistance of the 3-Hex/G+ was in part 
mediated by the binding of the classical pathway inhibitor C4BP. Blocking C4BP 
binding, increasing serum concentrations, or using a non-C4BP binding strain 
partially alleviated the serum resistance of the 3-Hex/G+ in the presence of 2C7-
murine. Despite low binding of 2C7-murine to the 3-Hex/G+ mutant, there was 
enough C3 deposited to mediate killing by PMNs via a process that was 
dependent upon both 2C7-murine and C’. 
Binding patterns of 2C7-Ximab(s) simulated 2C7-murine, that is 2-Hex/G+ >> 4-
Hex/G+ > 5-Hex/G+ >>> 3-Hex/G+. However, the concentrations (10 µg/mL and 
beyond) at which 2C7-Ximab binding could be appreciated to Ng HepI LOS 
mutants were higher than those for 2C7-murine (2 µg/mL and beyond). The 
possible reasons for this will be discussed later in this chapter. Of the three 2C7-
Ximab(s) (E430G Fc, WT Fc, and Null Fc), the E430G Fc was effective at a log10-
fold lesser concentration (31 µg/mL) compared to the WT Fc (316 µg/mL). The 
Null Fc had no bactericidal activity. The enhanced activity of E430G Fc was a 
direct consequence of greater C1q (and C3) recruitment compared to the WT Fc. 
2C7-Ximab E430G Fc kills three of the four HepI LOS mutants, 2-Hex/G+ (31 
µg/mL), 4-Hex/G+ (100 µg/mL), 5-Hex/G+ (178 µg/mL). The 3-Hex/G+ mutant 
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remained resistant even in the presence of 500 µg/mL of 2C7-Ximab E430G Fc 
(data not shown). The E430G Fc deposits more C3 compared to the WT Fc on 
the 3-Hex/G+ mutant at both 100 and 200 µg/mL. Nonetheless, even at 100 
µg/mL, the E430G Fc deposits enough C3 on the 3-Hex/G+ mutant to promote 
PMN mediated killing, whereas the WT Fc does not. Thus, even though 
statistically not significant, the higher level of C3 deposited by the E430G Fc 
(compared to WT Fc) may be functionally relevant. 
In vivo, the duration and burden of infection caused by the WT/G+, 5-Hex/G+ and 
4-Hex/G+ were shortened by intravaginal administration of 2C7-Ximab E430G. In 
contrast, the 2-Hex/G+ or 3-Hex/G+ mutants were significantly attenuated mice; 
administration of 2C7-Ximab E430G Fc did not further attenuate infection. This is 
probably because the 4-Hex HepI LOS structure present in all three of the more 
infective mutants (4-Hex/G+, 5-Hex/G+ and WT/G+) get sialylated which may 
confer a survival advantage in the murine colonization model (180). It is worth 
noting that inoculation of human male volunteers with (pre)sialylated MS11 
reduced infectivity (219); excessive sialylation of the LOS of the inoculum may 
impair ability of the bacteria to bind to ASGP-R on male urethral cells.  
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Significance of findings: novel insights into mAb 2C7 biology 
The lengths of Ng HepI LOS glycans affect murine and chimeric mAb 2C7 
binding. Two lactoses, one β-linked from HepI and another α-linked from HepII 
together comprise the mAb 2C7 epitope. It is plausible to hypothesize that the 
space created by the combination of these α- and β-linked lactoses create a 
pocket into which mAb 2C7 can enter and bind. As the length of the HepI chain 
with only β-linked Hex extensions (2-, 4- and 5-Hex) increases the Ab binding 
declines. This is probably due to steric hindrance which occludes the mAb 2C7 
binding pocket preventing entry and binding of the Ab. The terminal Gal in the 3-
Hex/G+ mutant which showed minimal Ab binding, is α-linked. α-bonds (axial 
bonds) are more rigid and offer lesser degrees of freedom of movement 
compared to β-linkages (equatorial bonds) (220). Therefore, the terminal Glc in 
3-Hex/G+ that extends perpendicularly from the plane of the 2-Hex HepI 
structure probably physically obstructs the mAb 2C7 epitope. The reader should 
note that the terminal α-linked HepI Hex extension in the 3-Hex/G+ mutant is in a 
different plane compared to the α-linked lactose on HepII. Thus, the two α-linked 
moieties may contribute differentially to antibody binding; the latter facilitating the 
creation of a binding pocket and the former obfuscating the pocket. A mAb, B5 
specific for the inner core of N. meningitidis recognizes strains with short (only a 
Glc, or a lactose) LOS Hex extensions from HepI and the phosphoethanolamine 
(PEA) at position 3 (endocyclic) of HepII. However, B5 reactivity is lost in strains 
with longer HepI extensions or with PEA at position 6 (exocyclic) probably 
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because of steric hindrance (221-223). Steric hindrance is also thought to inhibit 
Ab binding to core LPS structures in members of the Enterobacteriaceae family 
when rough (core OS only) LPS molecules are substituted with smooth (with 
repeating O-polysaccharides) LPS (224). Similarly, Coxiella burnetii, the 
causative agent of Q fever, expresses two forms of LPS, Phase I (smooth) and 
Phase II (rough). It has been demonstrated that Phase I LPS sterically hinders 
the binding of specific Ab(s) to Phase II Ag(s) (225). 
Low binding of a mAb 2C7-based vaccine or therapeutic Ab to some HepI 
glycans such as the 3-Hex/G+ could potentially pose an obstacle to mAb 2C7 
efficacy. Escape variants of multi-drug resistant Ng could precipitate outbreaks of 
gonorrhea that are untreatable/difficult to treat. The Pneumococcal Conjugate 
Vaccine 7 (PCV7), which targets the capsular polysaccharides of Streptococcus 
pneumoniae serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F was introduced in the 
US in 2000. However, shortly thereafter, the incidence of invasive pneumococcal 
disease in children below five years caused by non-vaccine serotypes, such as 
19A increased (226). Similarly, vaccination or infection with Phase I Coxiella 
burnetii elicit Ab(s) reactive with both virulent Phase I organisms (late Ab[s]; >20 
days) as well as avirulent Phase II organisms. However, vaccination with Phase 
II organisms induced Ab(s) that reacted only with Phase II organisms (225). 
Lack of bactericidal activity of mAb 2C7 against the 3-Hex/G+ mutant led to the 
description of an alternative mechanism of action for this Ab. Neutrophils infiltrate 
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the genital mucosae in large numbers in symptomatic gonococcal infections. Ng 
can survive and replicate within PMNs (22, 204-206, 208, 209). However, 
complement C3 mediated targeting of Ng to PMNs results in their killing (122). 
Sufficient C3 is deposited on 3-Hex/G+ by mAb 2C7 to cause killing by freshly 
isolated human PMNs. The importance of C3 opsonization in killing of the 3-
Hex/G+ by PMNs was further underscored in experiments that compared C3 
deposition and PMN killing between two 2C7-Ximab(s). Statistically insignificant 
enhancements in C3 deposition by the E430G Fc (compared to WT Fc) resulted 
in functionally significant differences in C3 dependent killing of the 3-Hex/G+ 
mutant by PMNs. Previous studies have demonstrated that mAb 2C7 
opsonization results in phagocytosis (without demonstrating killing) of Ng (227). 
However, studies described here demonstrate that Ab opsonization alone is not 
sufficient for killing. Activation of complement by mAb 2C7 is necessary for killing 
of Ng by PMNs. This knowledge can be harnessed to optimize the formulation of 
the candidate vaccine for maximum possible C’ activation to circumvent potential 
escape mutants (3-Hex/G+; discussed later in this chapter). 
The poor binding 2C7-murine to the 3-Hex/G+ mutant led to the animal studies to 
define the infectivity of the four individual HepI LOS mutants. While data 
gathered from the prior experimental human infection study demonstrates the 
propensity of Ng to switch to longer LOS glycans (199), experiments described in 
this dissertation demonstrate that even if a population of 3-Hex/G+ LOS 
expressing Ng arose under selection pressure, such variants may not be able to 
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establish a sustained infection. Furthermore, durable infections by longer HepI 
LOS glycan expressing mutants as well as higher bacterial burdens demonstrate 
that shorter HepI LOS glycans confer no advantage at least in the initial stages of 
infection. Moreover, infection in untreated animals with the 2-Hex/G+ and 3-
Hex/G+ lasted for the same duration as treated animals infected with the 4-
Hex/G+, 5-Hex/G+, and the WT/G+. This leads to the conclusion that there is a 
minimum duration before which 2C7-Ximab is effective. While the reason for this 
is unknown (a possible explanation discussed later in the chapter), it provides a 
rationale for hypothesizing that the lack of efficacy of 2C7-Ximab against the 2-
Hex/G+ and 3-Hex/G+ mutants may not be a major hurdle for its clinical success. 
Additionally, the 3-Hex/G+ mutant can be killed by PMNs (requires both Ab and 
C’). The issues of pv of the LOS and its impact on a 2C7-epitope based vaccine 
or therapeutic had not been considered before, but the results described here 
justify their further development.  
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Limitations of this study 
The genes encoding four of the LOS glycosyltransferases (Lgt[s]) are pv. While 
the genes themselves have been fixed (i.e. locked ‘ON’ or ‘OFF’) in the mutants 
used for the study, the levels of expression and/or activity of the four Lgt(s) could 
not be controlled. Thus, the 5-Hex and 3-Hex mutants also expressed shorter 
HepI LOS structures (hence >1 band on silver stain – Chapter II). This is 
because incomplete (shorter) LOS molecules are ‘flipped out’ to the surface 
before the terminal GalNAc/Gal has been added. However, such a situation will 
likely mimic conditions in human infection; a strain with a predominantly 3-Hex 
HepI LOS will express some amount of 2-Hex HepI LOS, and a strain with a 5-
Hex HepI LOS likely will also express 4-Hex HepI LOS. 
The 3-Hex/G+ mutant binds very little murine and chimeric mAb 2C7 compared 
to the other three mutants. Due to the presence of 2-Hex/G+ structures in the 3-
Hex/G+ mutant, it is possible that the small amount of Ab binding observed to 
this mutant is a result of the presence of the 2-Hex/G+ structure that forms the 
‘minimal’ 2C7 epitope and permits maximum mAb 2C7 binding. Similarly, the 5-
Hex/G+ mutant which also expresses 4-Hex HepI LOS structures binds a little 
less murine and chimeric mAb 2C7 compared to the 4-Hex/G+. It is also cleared 
significantly faster in the mouse model compared to the 4-Hex/G+ mutant. While 
it may be concluded that these effects are the result of the 5-Hex/G+ LOS 
structure, further delineation of the effects of the 5-Hex/G+ LOS was not 
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possible. In humans, the terminal GalNAc of the 5-Hex HepI is a target for natural 
bactericidal IgM (228); whether a similar mechanism is responsible for reduced 
fitness relative to the 4-Hex/G+ mutant in the mouse model is not clear. 
Neutrophils kill HepI LOS mutants (including 3-Hex/G+) opsonized with murine 
mAb 2C7/2C7-Ximab E430G Fc in the presence of C’. The exact mechanism of 
killing has not been explored here. Neutrophils can phagocytose complement 
opsonized bacteria, and subsequently phagosomes fuse with lysosomes where 
pathogens are killed. They can also be killed by PMNs by Neutrophil Extracellular 
Traps (NET). It has been shown that Ng can be killed by PMNs by both 
mechanisms (204, 229). Engagement of CR1 but not CR3 by C’ opsonized 
Staphylococcus aureus and Aggregatibacter actinomycetemcomitans (previously 
Actinobacillus actinomycetemcomitans) have been demonstrated to upregulate 
NET formation by PMNs. Opsonization with IgG alone does not cause NET 
formation (230). It would be of interest to explore how mAb 2C7 and C’ mediate 
killing of Ng by PMNs. 
Further, not all three 2C7-Ximab(s) were tested in the mouse model for efficacy 
of clearance. Nor was the superiority of 2C7-Ximab E430G Fc demonstrated in 
vivo for this strain. These issues however, were addressed in unpublished work 
by Gulati S et al. Prior to this experiment it was demonstrated that all three 2C7-
Ximab(s), E430G Fc and WT Fc cleared infections at high doses (10 µg/day 
given intravaginally); at this dose, the Null Fc mutant showed minimal activity; the 
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median time to clearance was 1 day earlier compared to saline-treated controls. 
At lower doses of 1 mg/day E430G Fc and WT Fc both cleared infection with 
similar efficacies, whereas the Null Fc showed no activity at all. Upon reducing 
the dose further to 0.1 mg/day, only E430G Fc, but not WT Fc, cleared infection. 
Therefore, only this 2C7-Ximab (E430G Fc) was chosen for studies described in 
this dissertation. Moreover, it has also been shown that E430G Fc fails to clear 
infection in C1q knockout mice (unpublished data – Gulati S. et al.) thereby 
underscoring the importance of C’ in mediating clearance of Ng. 
While intra-vaginal administration of 2C7-Ximab significantly shortened the 
duration of infection, the infected mice continued to shed Ng for 2 – 3 days. This 
is an observation consistent with prior active and passive immunization studies 
conducted with 2C7-murine (70). Why active or passive immunization does not 
prevent infection was outside the scope of the current study. A possible reason 
could be the administration of Premarin (estrogen) that was required for infection 
of mice. Administration of estrogen has been demonstrated not only to abrogate 
LPS induced production of IL-6 and IL-8, but also reverse the IL-1β induced 
stimulatory effect on NF-κB, IL-8 and TNF-α synthesis (231). TNF-α induces 
synthesis of C3 which is required for both the classical and alternative pathways 
of C’ (232), whereas the synthesis of C4 (required in the classical C’ pathway) is 
thought to be transcriptionally regulated in mice by NF-κB (233). As discussed in 
the preceding paragraph, C’ activation is necessary for clearance of infection by 
2C7-Ximab. In light of this, it is reasonable to speculate that the suppressive 
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effects of estrogen (last dose administered on day +2) on the synthesis of C’ 
proteins such as C3 and C4 delay the activation of the classical pathway by 2C7-
Ximab, thereby making the mice susceptible to Ng infections transiently. 
About 6% of circulating Ng strains lack the 2C7-epitope (87); loss of this epitope 
comes at a fitness cost (70, 89). In mice, strains capable of pv have a propensity 
to express the 2C7-epitope (89) and thus, it can be reasoned that in competition 
experiments mutants expressing this epitope have a survival advantage (70). It is 
also reported that Ng isolates lacking the 2C7-epitope are negatively selected in 
transgenic mice expressing CEACAM 3, 5, and 6 (89). The aims of this 
dissertation were determined using these rationales, however, to bolster the 
rationale behind the development of a 2C7-epitope based vaccine/therapeutic, it 
might be useful to assess the infectivity of 2C7-negative HepI mutants in the 
future. 
Finally, it is important to bear in mind that while one can make predictions about 
pathogenesis of Ng and the efficacy of a 2C7-epitope based vaccine or 
immunotherapeutic, definitive conclusions can only be made after appropriate 
human studies. There are several similarities between the murine vaginal 
colonization model and human Ng infections that merit the use of the model. The 
influx of PMNs (hallmark of clinical disease), elevated levels of IL-1, IL-6, and 
TNF-α are all observed in female BALB/c mice (234). Further, the pH of the 
cervix (site of infection in human females) and the murine vaginal pH are similar, 
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as are hormone regulated changes in mucosal viscosity and commensal flora 
(235). However, significant differences do exist between mice and humans; 
differences in sequences (that translate to binding differences) of CR3, FH, and 
C4BP, absence of CEACAM (receptors for the Ng surface protein Opa) being the 
most notable ones (235).  
 
151 
Future directions 
Although data from previous experimental human studies and the current work 
strongly suggests that the 2-Hex/G+ and 3-Hex/G+ mutants will perhaps be less 
infective in humans, the only way to establish this firmly would be to perform 
experimental human infections with these mutants. Such experiments would not 
only provide better insights into the impact of HepI LOS glycans in establishing 
infection, it would also provide an estimation of the risks posed by mutants that 
may escape a 2C7-epitope based vaccine or immunotherapeutic. 
Further, this dissertation establishes the critical role of human PMNs in killing the 
serum resistant (by classical pathway mediated MAC formation) 3-Hex/G+ 
mutants. Gulati S et al. (unpublished data) depleted murine PMNs and found no 
difference in clearance of WT FA1090 (predominantly 4-Hex/G+) infections in 
mice. However, a critical factor to consider in the interpretation of these results 
are the inherent differences between human and mouse PMNs; one such critical 
difference being in the phosphoinositide 3-kinase (PI3K) signaling pathway (236). 
PI3K plays an important role in the upregulation of C’ receptors such as CR3 
(237). In human PMNs there exist intracellular reservoirs of CR3 and CR1, and 
their expression on the surface is induced in the presence of stimuli (238). Since 
C’ is required for 2C7-murine or 2C7-Ximab mediated killing of the 3-Hex/G+ 
mutants, it is possible that due to the inherent differences between murine and 
human PMNs, their contribution to clearance of Ng infections have not been 
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appreciated in the mice. To assess the role of PMNs in clearance of Ng 
infections in the presence of 2C7-Ximab and C’, in vivo studies have to be 
conducted in ‘human immune system’ mice. One such in vivo model system 
where functional human neutrophils develop from CD34+ cord blood stem cells in 
NOD-scid-ɣc-/- has been described by Coughlan AM et al. (211). 
From a vaccine perspective, this body of work (along with unpublished work by 
Gulati et al) highlights the importance of C’ in anti-Ng defenses. This will prove 
critical in formulations development. The choice of adjuvants has been 
demonstrated to affect vaccine induced protection. For instance, Aventis 
Pasteur’s canarypox vector (ALVAC) – HIV + gp120 conferred protection in 
macaques against SIV when the vaccine was used with alum as an adjuvant but 
not when MF59 was used (239). Furthermore, adjuvants can also affect the 
isotype and subclass of IgG(s) produced; immunization of mice with the tumor Ag 
MUC1 peptide with GM-CSF induced IgG1 and IgG2b in WT mice and IgM in 
MUC1-Tg mice, whereas with SB-AS2 the same immunogen induced IgG1, 
IgG2b and IgG3 in both WT and MUC1-Tg mice (240). Adjuvants have the 
potential to direct Ab isotype, subclass, and glycosylation. Thus, during 
development of the mAb 2C7-based candidate vaccine, multiple adjuvants 
should be tested. Subsequent to in vivo testing of vaccine candidates, serum 
from vaccinated animals could then be used to isolate Ng specific Ab(s) in order 
to understand Ab subclass and glycosylation patterns that correlate with maximal 
protection. Further, animals should be injected at multiple sites (subcutaneous, 
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intra-muscular, etc.) in protection experiments to determine the route of 
administration of the vaccine. 
The hyperactive 2C7-Ximab, E430G Fc (human IgG1) is bactericidal at a log10-
fold higher concentration compared to murine mAb2C7 (mouse IgG3). Multiple 
factors could affect functional efficacy such as Ab subclass (IgG3 activates C’ 
better than IgG1), species and subclass specific differences in C’ activation 
(human versus murine IgG3 or IgG1), glycosylation at N297. All these aspects 
merit further investigation. Further, the amount of Ab bound, itself could modulate 
function. While binding of 2C7-murine can be detected by FCM even at 
concentrations below 1 µg/mL, 2C7-Ximab binding was only appreciable at 
concentrations of 10 µg/mL and beyond. Thus, endeavors should be made to 
enhance binding efficacy during complete humanization of the mAb 2C7-based 
immunotherapeutic. The current 2C7-Ximab constructs are direct grafts of the 
murine Fv region into a human IgG1 Fc region. Since a peptide mimic of the 
2C7-epitope is already available; it would be informative to co-crystalize the Ab 
with its epitope. In protein-protein interactions, whilst the overall interfaces can be 
quite large, not all amino acids contribute to the same extent. Only a small subset 
of contact residues has a critical effect on binding (241, 242). These amino acids 
can be determined by phage display using combinatorial alanine scanning 
mutagenesis, and subsequently optimized to enhance binding affinity of the 
humanized Ab (243). Alanine scanning mutagenesis has been previously used to 
map functional paratopes on bNAb(s) 4E11 and 4E5A against Dengue virus 
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(DENV) serotypes 1 – 4 (244); while 4E11 is a naturally occurring bNAb and 
reacts only with DENV 1 – 3, 4E5A generated by mutating 4E11 neutralizes all 
four DENV serotypes (245). Such an approach may successfully enhance the 
binding affinity of a fully humanized mAb 2C7 thus lowering the dose required for 
treatment. 
In the clinical laboratory, Gram-stained smears of specimens from males show 
predominantly PMNs with few epithelial cells. Endocervical specimens show a 
similar picture, but is not diagnostic. There has been no formal analysis of the 
inflammatory cell landscape in Ng infected tissues. In healthy human females, 
the primary inflammatory cells are PMNs, followed by Natural Killer (NK) cells. 
Significantly fewer macrophages are observed (246). An understanding of the 
inflammatory cell landscape in Ng infected tissues will be invaluable. Such 
information can be utilized to further engineer the Fc region of a humanized 2C7 
to recruit multiple host defenses against Ng. The data can also be potentially 
mined to fine tune the immune response to a mAb 2C7-based vaccine by using 
adjuvants that direct a response for optimal recruitment of host defenses. 
NK cells could be of particular interest. Perforin produced by NK cells belong to 
the same class of cytolytic toxins as complement C9; both possess the 
MACPF/CDC domain which inserts into cellular membranes. Perforin released 
from NK cells have been demonstrated to insert into considerably tough mycolic 
acid cell walls in Mycobacterium tuberculosis (Mtb). It has also been shown that 
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granulysin has a synergistic effect on the anti-Mtb activity of NK cells (247). 
Compared to Mtb, the cell wall of Ng is considerable weaker, and therefore one 
can reason that the gonococcal outer membrane would be susceptible to perforin 
mediated damage. Thus, it would be of interest to assay if a vaccine Ab, 2C7-
Ximab E430G Fc, or a fully humanized mAb 2C7 can mediate this activity by 
engaging FcƔR(s) on human NK cells. This could then serve as an added 
redundant mechanism of action of the immunotherapeutic. 
Finally, antibodies may sometimes exacerbate infections instead of alleviating 
them. This phenomenon is known as antibody-dependent enhancement (ADE). 
ADE is perhaps best appreciated with a second Dengue viral infection where the 
subsequent virus is of a different serotype. Nonetheless, ADE has also been 
reported for HIV, Ebola, Ross River virus (248). Ng has been shown to survive 
within both male and female epithelial cells (249, 250). Moreover, once inside 
epithelial cells, Ng could possibly be subsequently disseminated. FcƔR(s) 
(FcƔRII and FcƔRIII, but not FcƔRI) have been detected in vaginal, ectocervical, 
and endocervical cells (251). They have also been reported on male urethral 
epithelial cells (252). Therefore, it is reasonable to hypothesize that a 2C7-
epitope based vaccine induced Ab, or humanized mAb 2C7 opsonized Ng might 
employ FcƔR(s) as a portal of entry into cells. They may subsequently establish 
latent/sub-clinical infections or may be disseminated. Thus, histopathology 
studies in treated animals in the murine vaginal colonization model to rule out this 
possibility are merited.  
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APPENDIX 
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The previous chapters describe experiments and results pertinent to the aims of 
this dissertation. However, there are some questions that had to be answered 
prior to addressing my primary objectives, or that are of interest to readers, and 
is the subject of this section.  
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Fitness in vitro of mAb 2C7-reactive HepI glycan mutants 
Prior to addressing the in vivo fitness of the HepI LOS mutants, I had to ensure 
that none of the mutants had an in vitro growth defect. This was assessed by 
comparing the growth curves of the four mAb 2C7-reactive HepI LOS mutants 
with MS11 WT (Fig. 1). All four HepI glycan mutants showed similar growth 
curves compared to MS11 WT.  
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Figure 1. Growth curves of Ng LOS mutants. All four mAb 2C7-reactive HepI 
LOS mutants: 2-Hex/G+, 3-Hex/G+, 4-Hex/G+, 5-Hex/G+, as well as MS11 WT 
showed similar growth curves. None of the mutants had a growth defect in vitro 
in liquid medium. Overnight cultures from CA plates were suspended in complete 
Morse medium containing Isovitalex (9 parts Morse A, 1 part Morse B;100 µL 
Isovitalex per 10 mL complete Morse medium) to an initial absorbance (λ600) of 
0.1 using a Spectronic 20+ spectrophotometer. Subsequently absorbances were 
measured at 1 h intervals for up to 6 h. Each data point is the mean of 2 
experiments (±range).  
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Serum bactericidal activity of NHS on HepI LOS mutants 
Although not an objective, the ability NHS (i.e., that contains natural Ab) to 
activate the classical complement pathway on HepI LOS mutants was also 
assessed. Ng expressing 2-Hex/G+ and 3-Hex/G+ mutants were serum resistant 
whereas a mutant that expressed a terminal GalNAc (5-Hex/G+ in my studies) 
was completely sensitive (Fig. 2). Mutants expressing the LNnT (4-Hex/G+) LOS 
structure showed intermediate serum resistance (Fig. 2). The MS11 WT (MS11 
4/3/1) is the parent strain from which the HepI LOS mutants were derived. My 
results were similar to those observed previously (82, 164, 184). However, while 
similar interpretations can be drawn from the earlier publications, this is, to the 
best of our knowledge the first systematic evaluation of serum susceptibilities (to 
NHS) of Ng expressing fixed HepI LOS structures using mutants in an isogenic 
background.  
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Figure 2. 
Serum 
bactericidal 
assays with 
20% NHS. In 
the absence 
of any 
exogenously 
added Ab(s), 
the 2-Hex/G+ 
and 3-Hex/G+ 
mutants are 
resistant to C’-
mediated 
bactericidal effects of NHS. The 4-Hex/G+ mutant was intermediately resistant 
and the 5-Hex/G+ mutant was completely killed. The parent MS11 WT strain was 
also intermediately resistant (F62 – sensitive control, 15253 – resistant control). 
Each bar represents mean of 2 replicates (±SEM) using two different NHS 
sources. Comparisons between mutants were made using ordinary one-way 
ANOVA (Tukey’s multiple comparison test). Overall P value was <0.0001. (*, P < 
0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001). Serum bactericidal assays 
were done as described previously. Briefly, about 2000 CFU of bacteria were 
incubated with 20% NHS for 30 min at 37 °C with 5% CO2 without shaking for 30 
min. Aliquots were plated in duplicates on chocolate agar at T= 0 and 30 min. 
Colonies were counted the following day and the number of colonies at T30 were 
expressed as a percent of the number of colonies at T0 to calculate survival.  
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HepI LOS glycans regulate binding of factor H to Neisseria gonorrhoeae 
FH is a negative regulator or the alternative C’ cascade. C3b deposited by the 
classical pathway can recruit the alternate complement pathway positive 
feedback loop. Thus, it was important to assess binding of FH to the HepI LOS 
mutants. HepI LOS mutants regulate binding of FH to Ng; FH binding decreases 
as HepI glycan length increases. The differences however, were significant only 
for the 2-Hex/G+ mutant (Fig. 3). Nonetheless, mAb 2C7, which binds best to the 
2-Hex/G+ mutant, activates the classical pathway sufficiently to overcome the 
effects of FH. Similar trends were observed with C4BP (negative regulator of the 
classical cascade). I hypothesize that longer HepI glycan structures may 
sterically hinder binding of FH and C4BP to their ligand(s) on the surface of Ng.  
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Figure 3. FH binding to the MS11 lgtG ‘ON’ (G+) mutants. HepI LOS glycans 
modulate FH binding. FH binding declines as HepI LOS glycan length increases. 
Significantly higher binding is observed to the 2-Hex/G+ mutant compared to the 
other HepI LOS mutants. Bacteria were incubated with 20% heat inactivated 
human complement for 30 min at 37 °C and bound FH was detected with 
polyclonal goat anti-human FH, followed by biotinylated anti-goat IgG (Molecular 
Probes), followed by Neuravidin conjugated DyLight 633 (ThermoFisher 
Scientific). Fluorescence was measured using a BD LSRII. The number 
alongside each bar represents the median fluorescence intensity. Each bar is the 
mean of 5 replicates (±SEM). Mutants were compared using ordinary one-way 
ANOVA. Overall P value <0.0001 (****, P < 0.0001).  
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Effect of sialic acid on mAb 2C7 function 
The LNnT (4-Hex) LOS structure of Ng becomes sialylated in vivo. Sialylation of 
the LNnT enhances FH binding to Ng that inhibits the alternative pathway. C3b 
deposited by the classical pathway activates the alternate pathway. Therefore, C’ 
activation on the 4-Hex/G+ mutant by mAb 2C7 was studied when bacteria were 
grown in the presence of increasing concentrations of CMP-Neu5Ac. I observed 
a progressive increase in serum resistance with increasing concentrations of 
CMP-Neu5Ac. 2C7-murine at a concentration of 4 µg/ml killed approximately 
50% of the 4-Hex/G+ mutants grown in the presence of 2 µg/mL of CMP-Neu5Ac 
(Fig. 4). The mutant becomes fully resistant when grown in presence of 40 µg/mL 
of CMP-Neu5Ac (data not shown).  
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Figure 4. Serum bactericidal activity of 2C7-murine on sialylated 4-Hex/G+. 
Sialylation of 4-Hex/G+ makes it resistant to C’ mediated killing in the presence 
of 2C7-murine on account of increased FH binding. Serum bactericidal assays 
were done as described previously with 4-Hex/G+ grown in the presence of 
varying amounts of CMP-Neu5Ac. Each bar is the mean of 3 replicates (±SEM). 
Groups were compared using ordinary one-way ANOVA with an overall P value 
of 0.0005 (*, P < 0.05; **, P < 0.01; ***, P < 0.001).  
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Plating efficiency of Ng in the presence of antibiotics 
Antibiotics sometimes decrease the plating efficiencies of bacteria. Therefore, to 
make comparisons across the various mutants in vivo, where daily CFU were 
determined by plating on CA supplemented with vancomycin, colistin, neomycin, 
trimethoprim and streptomycin (CA-VCNTS) it was important to determine the 
plating efficiencies of the HepI LOS mutants. There were no differences in CFU 
counts across the four HepI mutants or MS11 WT (Fig. 5). Further, there were no 
differences in the number of colonies on CA versus CA-VCNTS (Fig. 5).  
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Figure 5. Plating efficiencies on CA versus CA-VCNTS agar. There were no 
differences in plating efficiencies when bacteria were cultured on CA-VCNTS 
compared to CA. The four Ng LOS mutants and MS11 WT were grown overnight 
on CA and suspended to an initial absorbance of 0.1 in normal saline (0.9% 
NaCl). Subsequently, the suspensions were further diluted in normal saline (1:2). 
Twenty µL of this diluted suspension were plated on CA as well as CA-VCNTS 
agar. Twenty µL of 10-fold serial dilutions of the diluted bacterial suspension 
were also plated on CA and CA-VCNTS agar plates. Plates were incubated 
overnight at 37 °C in the presence of 5% CO2 and CFU were counted to 
determine if there were differences in plating efficiencies between the two media. 
Each bar is the mean of 2 experiments (±range).  
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Effect of piliation on murine infection 
Pili are considered to be important adhesins and are hypothesized to play an 
important role in human infections. Although controversial, pili are thought to bind 
CD46 r 
eceptors expressed on the human vaginal epithelium (31). The strain of MS11 
used as a background for constructing the LOS mutants in this study does not 
constitutively express pili, but does so when induced with IPTG (which was 
necessary to transform the strain). Piliation has been previously described to be 
inconsequential for murine vaginal infections (126). However, these experiments 
were conducted with non-piliated variants. Variants may start expressing pili 
once in the murine tract. Therefore, before the LOS mutants were constructed, a 
pilot mouse experiment was done to verify whether piliation is indeed 
unimportant in the colonization of murine vaginal tracts. The background strain 
MS11 WT (4/3/1; pilEind) remains non-piliated in the murine vaginal tract. The 
results confirmed previous observations. There were no differences in the 
duration of infection or CFU counts between piliated and non-piliated MS11 in a 
co-infection study (Fig. 6).  
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Figure 6. In vivo coinfection 
studies with piliated and 
non-piliated Ng. Pilus does 
not impact ability of Ng to 
colonize mice. This confirms 
studies conducted earlier 
with piliated and non-
piliated variants of Ng. 
Twelve 6-8 weeks old 
BABL/c mice were infected 
as described in Chapter III 
with a one to one mixture of 
piliated MS11 (VD300; +pilE 
with an erythromycin 
resistance cassette) and 
non-piliated MS11 WT 
(4/3/1; pilEInd; background 
strain for mutants described 
in this dissertation). Vaginal 
swabs were plated on CA-
VCNTS and CA-VCNTS-
Erm (100 µg/mL). The 
number of colonies on CA-
VCNTS-Erm were subtracted from the number of colonies on CA-VCNTS to 
decipher the number of MS11 WT (4/3/1) colonies. The experiment was 
terminated after 5 d as: (a) Both the piliated and the non-piliated showed similar 
patterns of infection and (b) More or less equivalent numbers of CFU of both 
piliated and non-piliated mutants were recovered (Mean of CFU/100 µL [±SEM]).  
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